Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,000 | 2022-11-22 00:00:00 UTC | FOCUS-Generic drugmakers Teva and Sandoz make major push to biosimilars | ABBV | https://www.nasdaq.com/articles/focus-generic-drugmakers-teva-and-sandoz-make-major-push-to-biosimilars | null | null | By Natalie Grover and Steven Scheer
Nov 22 (Reuters) - Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer – aiming to increase their share of ... | Executives from Teva TEVA.TA, TEVA.N and Sandoz said they are targeting top-selling biologics such as Humira, AbbVie Inc’s ABBV.N top-selling arthritis drug, which came off-patent in Europe and is due to come off-patent in the U.S. next year. Biologics are complex molecules cultivated inside living cells, making it imp... | Executives from Teva TEVA.TA, TEVA.N and Sandoz said they are targeting top-selling biologics such as Humira, AbbVie Inc’s ABBV.N top-selling arthritis drug, which came off-patent in Europe and is due to come off-patent in the U.S. next year. By Natalie Grover and Steven Scheer Nov 22 (Reuters) - Generic drug makers Te... | Executives from Teva TEVA.TA, TEVA.N and Sandoz said they are targeting top-selling biologics such as Humira, AbbVie Inc’s ABBV.N top-selling arthritis drug, which came off-patent in Europe and is due to come off-patent in the U.S. next year. By Natalie Grover and Steven Scheer Nov 22 (Reuters) - Generic drug makers Te... | Executives from Teva TEVA.TA, TEVA.N and Sandoz said they are targeting top-selling biologics such as Humira, AbbVie Inc’s ABBV.N top-selling arthritis drug, which came off-patent in Europe and is due to come off-patent in the U.S. next year. Teva currently has three approved biosimilars and 13 in development. While mo... |
23,001 | 2022-11-22 00:00:00 UTC | Want Passive Income in 2023? Buy These Dividend Kings | ABBV | https://www.nasdaq.com/articles/want-passive-income-in-2023-buy-these-dividend-kings | null | null | Today's market is tough. And your portfolio may be suffering. But if you invest in dividend stocks, the picture may begin to look brighter. These companies pay you annually -- just for owning their shares. So, in good times and in bad, you can rely on this passive income to lift the value of your holdings.
Where do you... | But AbbVie expects its two newer immunology drugs, together, to eventually top Humira's peak sales. AbbVie AbbVie (NYSE: ABBV) launched back in 2013 as a spinoff of Abbott Laboratories (NYSE: ABT). Since that time, AbbVie has raised its dividend by more than 250%. | AbbVie AbbVie (NYSE: ABBV) launched back in 2013 as a spinoff of Abbott Laboratories (NYSE: ABT). Since that time, AbbVie has raised its dividend by more than 250%. But you'll want to own AbbVie for more than its dividend. | Abbott Abbott and AbbVie share a common history -- and that includes prioritizing dividends. AbbVie AbbVie (NYSE: ABBV) launched back in 2013 as a spinoff of Abbott Laboratories (NYSE: ABT). Since that time, AbbVie has raised its dividend by more than 250%. | But you'll want to own AbbVie for more than its dividend. AbbVie AbbVie (NYSE: ABBV) launched back in 2013 as a spinoff of Abbott Laboratories (NYSE: ABT). Since that time, AbbVie has raised its dividend by more than 250%. |
23,002 | 2022-11-21 00:00:00 UTC | 3 Top Dividend Stocks to Buy Now With Yields of 3.4% or More | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-to-buy-now-with-yields-of-3.4-or-more | null | null | Are you looking for reliable dividend-paying stocks that offer juicy yields and the ability to raise their payouts much further by the time you're ready to retire? If so, these three stocks from the healthcare and finance sectors have you covered.
Right now all three of these top dividend stocks offer yields above the ... | A long list of prescription drugs helped AbbVie generate an impressive $21 billion in free cash flow over the past twelve months. AbbVie AbbVie (NYSE: ABBV) is the biopharmaceutical company behind Humira, a top-selling drug for arthritis and psoriasis. Next year, biosimilars finally entering the U.S. market will weigh ... | AbbVie AbbVie (NYSE: ABBV) is the biopharmaceutical company behind Humira, a top-selling drug for arthritis and psoriasis. Next year, biosimilars finally entering the U.S. market will weigh heavily on AbbVie's top line, as well. Despite Humira's impending loss of exclusivity, AbbVie looks like a good dividend stock to ... | AbbVie AbbVie (NYSE: ABBV) is the biopharmaceutical company behind Humira, a top-selling drug for arthritis and psoriasis. Next year, biosimilars finally entering the U.S. market will weigh heavily on AbbVie's top line, as well. Despite Humira's impending loss of exclusivity, AbbVie looks like a good dividend stock to ... | AbbVie AbbVie (NYSE: ABBV) is the biopharmaceutical company behind Humira, a top-selling drug for arthritis and psoriasis. Next year, biosimilars finally entering the U.S. market will weigh heavily on AbbVie's top line, as well. Despite Humira's impending loss of exclusivity, AbbVie looks like a good dividend stock to ... |
23,003 | 2022-11-20 00:00:00 UTC | If You Invested $5,000 In InMode Stock In 2020, Here's How Much Money You'd Have Today | ABBV | https://www.nasdaq.com/articles/if-you-invested-%245000-in-inmode-stock-in-2020-heres-how-much-money-youd-have-today | null | null | InMode (NASDAQ: INMD) is a growth stock unlike any other, and it's also one of my biggest holdings. This medical aesthetics company hails from Israel, and it makes technologies that enable minimally invasive beauty treatments, ranging from skin tightening to body contouring. That means it stands to steal market share f... | Management cites such companies as AbbVie subsidiary Allergan, which makes Botox, as contestants for its market. In fact, compared to five years ago, the company's cost of goods sold (COGS) and total expenses have fallen as a percentage of its quarterly revenue, and its profit margin actually widened. The point is that... | Management cites such companies as AbbVie subsidiary Allergan, which makes Botox, as contestants for its market. That means it stands to steal market share from traditional, non-invasive beauty techniques like laser treatments as well as invasive approaches like plastic surgery. This growth stock delivered massive retu... | Management cites such companies as AbbVie subsidiary Allergan, which makes Botox, as contestants for its market. This growth stock delivered massive returns Investing in InMode in early 2020 was a smart move. Perhaps the biggest risk to investors who buy InMode stock today is potential competition from other companies ... | Management cites such companies as AbbVie subsidiary Allergan, which makes Botox, as contestants for its market. InMode (NASDAQ: INMD) is a growth stock unlike any other, and it's also one of my biggest holdings. In fact, compared to five years ago, the company's cost of goods sold (COGS) and total expenses have fallen... |
23,004 | 2022-11-19 00:00:00 UTC | 2 Breakout Growth Stocks to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/2-breakout-growth-stocks-to-buy-for-the-long-haul-0 | null | null | Definitive Healthcare (NASDAQ: DH) and Elevance Health (NYSE: ELV) may not be household names, but these two healthcare stocks in the Russell 1000 Index are prime examples of breakout growth stocks that investors should be considering.
Other than their strong prospects, the two stocks aren't much alike. Definitive, fou... | Definitive Healthcare simplifies medical sales Definitive Healthcare just went public last year through an initial public offering, but many of its clients are big players in healthcare, such as AbbVie, Siemens Healthineers, and AstraZeneca. See the 10 stocks *Stock Advisor returns as of November 7, 2022 Jim Halley has... | Definitive Healthcare simplifies medical sales Definitive Healthcare just went public last year through an initial public offering, but many of its clients are big players in healthcare, such as AbbVie, Siemens Healthineers, and AstraZeneca. See the 10 stocks *Stock Advisor returns as of November 7, 2022 Jim Halley has... | Definitive Healthcare simplifies medical sales Definitive Healthcare just went public last year through an initial public offering, but many of its clients are big players in healthcare, such as AbbVie, Siemens Healthineers, and AstraZeneca. See the 10 stocks *Stock Advisor returns as of November 7, 2022 Jim Halley has... | Definitive Healthcare simplifies medical sales Definitive Healthcare just went public last year through an initial public offering, but many of its clients are big players in healthcare, such as AbbVie, Siemens Healthineers, and AstraZeneca. See the 10 stocks *Stock Advisor returns as of November 7, 2022 Jim Halley has... |
23,005 | 2022-11-18 00:00:00 UTC | CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron | ABBV | https://www.nasdaq.com/articles/cytomx-ctmx-stock-surges-on-oncology-deal-with-regeneron | null | null | Shares of clinical-stage, oncology-focused biopharmaceutical company CytomX Therapeutics, Inc. CTMX skyrocketed 32.2% after the company announced a collaboration and licensing agreement with biotech giant, Regeneron Pharmaceuticals, Inc. REGN.
Both companies have collaborated to create conditionally-activated investiga... | It has demonstrated encouraging antitumor activity in patients with squamous non-small cell lung cancer and is being developed in collaboration with AbbVie. CytomX also has strategic collaborations with bigwigs like AbbVie ABBV, Amgen AMGN, Astellas, and Bristol Myers Squibb. AbbVie Inc. (ABBV): Free Stock Analysis Rep... | CytomX also has strategic collaborations with bigwigs like AbbVie ABBV, Amgen AMGN, Astellas, and Bristol Myers Squibb. It has demonstrated encouraging antitumor activity in patients with squamous non-small cell lung cancer and is being developed in collaboration with AbbVie. AbbVie Inc. (ABBV): Free Stock Analysis Rep... | CytomX also has strategic collaborations with bigwigs like AbbVie ABBV, Amgen AMGN, Astellas, and Bristol Myers Squibb. It has demonstrated encouraging antitumor activity in patients with squamous non-small cell lung cancer and is being developed in collaboration with AbbVie. AbbVie Inc. (ABBV): Free Stock Analysis Rep... | CytomX also has strategic collaborations with bigwigs like AbbVie ABBV, Amgen AMGN, Astellas, and Bristol Myers Squibb. It has demonstrated encouraging antitumor activity in patients with squamous non-small cell lung cancer and is being developed in collaboration with AbbVie. AbbVie Inc. (ABBV): Free Stock Analysis Rep... |
23,006 | 2022-11-17 00:00:00 UTC | Key Factors Driving Amgen's (AMGN) Outperformance This Year | ABBV | https://www.nasdaq.com/articles/key-factors-driving-amgens-amgn-outperformance-this-year | null | null | Amgen AMGN stock has risen 38.2% this year so far against a decline of 23.4% for the industry.
Image Source: Zacks Investment Research
Here we discuss the factors for the stock's outperformance. Amgen’s key drugs like Prolia, Repatha and Otezla are aiding sales, driven by volume growth. These drugs are gaining consist... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen will be one of the first companies to launch its biosimilar of AbbVie’s Humira in early 2023. Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the Un... |
23,007 | 2022-11-16 00:00:00 UTC | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar-3 | null | null | The First Trust Morningstar Dividend Leaders ETF (FDL) was launched on 03/09/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by First Trust Advisors. It has amassed assets over $4.28 billion, making it o... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 9.10% of total assets, followed by Abbvie Inc. (ABBV) and Verizon Communications Inc. (VZ). AbbVie Inc. (ABBV): Free Stock Analysis Report The First Trust Morningstar Dividend Leaders ETF (FDL) was launched on 03/09/2006, and is a passivel... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 9.10% of total assets, followed by Abbvie Inc. (ABBV) and Verizon Communications Inc. (VZ). AbbVie Inc. (ABBV): Free Stock Analysis Report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 9.10% of total assets, followed by Abbvie Inc. (ABBV) and Verizon Communications Inc. (VZ). AbbVie Inc. (ABBV): Free Stock Analysis Report Alternatives First Trust Morningstar Dividend Leaders ETF holds a Zacks ETF Rank of 2 (Buy), which i... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 9.10% of total assets, followed by Abbvie Inc. (ABBV) and Verizon Communications Inc. (VZ). AbbVie Inc. (ABBV): Free Stock Analysis Report The First Trust Morningstar Dividend Leaders ETF (FDL) was launched on 03/09/2006, and is a passivel... |
23,008 | 2022-11-15 00:00:00 UTC | 3 Pharmaceutical Stocks For Your November 2022 Watchlist | ABBV | https://www.nasdaq.com/articles/3-pharmaceutical-stocks-for-your-november-2022-watchlist | null | null | Pharmaceutical stocks are an important part of any well-rounded investment portfolio. They offer the potential for both high returns and low risk, making them ideal for investors of all types. Pharmaceutical stocks are a good investment for many reasons.
For one, the global population is aging, and as people age, they ... | Richard A. Gonzalez, chairman and CEO at AbbVie commented, “We continue to see strong momentum from our key immunology assets, Skyrizi and Rinvoq, and this performance – combined with strength from other growth drivers within our diverse portfolio – has mitigated the impact of temporary economic headwinds on our aesthe... | Pharmaceutical Stocks To Watch Today AbbVie Inc. (NYSE: ABBV) Amgen Inc. (NYSE: AMGN) Bristol Myers Squibb Company (NYSE: BMY) AbbVie (ABBV Stock) Leading off, AbbVie (ABBV) is a research-based biopharmaceutical company that discovers, develops, manufactures, and markets innovative therapies used to treat some of the w... | Pharmaceutical Stocks To Watch Today AbbVie Inc. (NYSE: ABBV) Amgen Inc. (NYSE: AMGN) Bristol Myers Squibb Company (NYSE: BMY) AbbVie (ABBV Stock) Leading off, AbbVie (ABBV) is a research-based biopharmaceutical company that discovers, develops, manufactures, and markets innovative therapies used to treat some of the w... | Pharmaceutical Stocks To Watch Today AbbVie Inc. (NYSE: ABBV) Amgen Inc. (NYSE: AMGN) Bristol Myers Squibb Company (NYSE: BMY) AbbVie (ABBV Stock) Leading off, AbbVie (ABBV) is a research-based biopharmaceutical company that discovers, develops, manufactures, and markets innovative therapies used to treat some of the w... |
23,009 | 2022-11-14 00:00:00 UTC | Noteworthy Monday Option Activity: BA, CHRD, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-ba-chrd-abbv | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Boeing Co. (Symbol: BA), where a total of 55,921 contracts have traded so far, representing approximately 5.6 million underlying shares. That amounts to about 54.9% of BA's average daily trading volume over the ... | Particularly high volume was seen for the $155 strike call option expiring November 18, 2022, with 2,255 contracts trading so far today, representing approximately 225,500 underlying shares of ABBV. Below is a chart showing CHRD's trailing twelve month trading history, with the $130 strike highlighted in orange: And Ab... | Below is a chart showing CHRD's trailing twelve month trading history, with the $130 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 29,113 contracts, representing approximately 2.9 million underlying shares or approximately 54.1% of ABBV's average daily trading volume over the... | Below is a chart showing CHRD's trailing twelve month trading history, with the $130 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 29,113 contracts, representing approximately 2.9 million underlying shares or approximately 54.1% of ABBV's average daily trading volume over the... | Below is a chart showing CHRD's trailing twelve month trading history, with the $130 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 29,113 contracts, representing approximately 2.9 million underlying shares or approximately 54.1% of ABBV's average daily trading volume over the... |
23,010 | 2022-11-14 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-1 | null | null | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned +5.1%, compared to the Zacks S&P 500 composite's +11.4% change. During th... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals indus... | Last Reported Results and Surprise History AbbVie reported revenues of $14.81 billion in the last reported quarter, representing a year-over-year change of +3.3%. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVi... | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 8.2%. AbbVie is expected to post earnings of $3.70 per share for the current quarter, representing a year-over-year change of +11.8%. | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 8.2%. AbbVie is expected to post earnings of $3.70 per share for the current quarter, representing a year-over-year change of +11.8%. |
23,011 | 2022-11-13 00:00:00 UTC | Is A Fall Imminent For Merck Stock After A 12% Rise In A Month? | ABBV | https://www.nasdaq.com/articles/is-a-fall-imminent-for-merck-stock-after-a-12-rise-in-a-month | null | null | Merck stock (NYSE: MRK) is up 12% in a month, outperforming the broader S&P500 index, up 5%. The rise in MRK stock can be attributed to the upbeat Q3 earnings it reported in late October. Its top and bottom line were well above our estimates, driven by market share gains for some of its drugs.
Merck’s revenue of $15.0 ... | We have assigned a slightly higher multiple for Merck than its historical average due to robust earnings growth expected in the coming years, driven by continued market share gains for Keytruda. Just three of those resulted in MRK stock rising over the subsequent one-month period (twenty-one trading days). Furthermore,... | We have assigned a slightly higher multiple for Merck than its historical average due to robust earnings growth expected in the coming years, driven by continued market share gains for Keytruda. Merck (MRK) Stock Return (Recent) Comparison With Peers And S&P500 Five-Day Return: BMY highest at 3.0%; PFE lowest at -0.7% ... | After moving 3.2% or more over ten days, the stock rose in the next ten days on 52% of the occasions After moving 11.6% or more over a twenty-one-day period, the stock rose on 14% of the occasions in the next twenty-one days. Merck (MRK) Stock Return (Recent) Comparison With Peers And S&P500 Five-Day Return: BMY highes... | We estimate Merck’s Valuation to be around $114 per share, which is about 12% above the current market price of $102. We have assigned a slightly higher multiple for Merck than its historical average due to robust earnings growth expected in the coming years, driven by continued market share gains for Keytruda. MRK sto... |
23,012 | 2022-11-13 00:00:00 UTC | The 7 Best Stocks for Retirement | ABBV | https://www.nasdaq.com/articles/the-7-best-stocks-for-retirement | null | null | With corporate pensions largely becoming an anachronistic relic, it’s never been more important for investors to plan for their golden years. However, with the combination of broader market volatility and the Federal Reserve’s interest rate hikes (and all that this action encompasses), the backdrop practically bolsters... | AbbVie (NYSE:ABBV) A pharmaceutical giant, AbbVie draws intrigue because of its acquisition of Botox. It’s a cynical take, sure, but it’s also one that could make ABBV one of the best stocks for retirement. By the numbers, AbbVie continues to attract investors. | AbbVie (NYSE:ABBV) A pharmaceutical giant, AbbVie draws intrigue because of its acquisition of Botox. It’s a cynical take, sure, but it’s also one that could make ABBV one of the best stocks for retirement. By the numbers, AbbVie continues to attract investors. | Turning to Wall Street, ABBV stock has a Moderate Buy consensus rating based on five Buys, six Holds, and one Sell rating. AbbVie (NYSE:ABBV) A pharmaceutical giant, AbbVie draws intrigue because of its acquisition of Botox. It’s a cynical take, sure, but it’s also one that could make ABBV one of the best stocks for re... | AbbVie (NYSE:ABBV) A pharmaceutical giant, AbbVie draws intrigue because of its acquisition of Botox. It’s a cynical take, sure, but it’s also one that could make ABBV one of the best stocks for retirement. By the numbers, AbbVie continues to attract investors. |
23,013 | 2022-11-13 00:00:00 UTC | 2 Top Stocks to Buy in November and Hold Forever | ABBV | https://www.nasdaq.com/articles/2-top-stocks-to-buy-in-november-and-hold-forever | null | null | Earnings reports can be an investor's best friend. They don't just tell us about recent revenue and profit. They also offer us clues about a company's future. These reports don't have to be 100% positive. But if certain important points are bright, we might be looking at a buying opportunity.
That's the case for both A... | AbbVie's super blockbuster immunology drug Humira is set to face U.S. competition as of next year. In the third-quarter earnings report, AbbVie said both drugs are set to generate $7.5 billion in revenue this year. AbbVie shares today are trading for 10 times forward earnings estimates, down from more than 12 earlier t... | In the third-quarter earnings report, AbbVie said both drugs are set to generate $7.5 billion in revenue this year. AbbVie shares today are trading for 10 times forward earnings estimates, down from more than 12 earlier this year. That's the case for both AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG). | In the third-quarter earnings report, AbbVie said both drugs are set to generate $7.5 billion in revenue this year. Like AbbVie, Intuitive has a history of earnings growth over time. That's the case for both AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG). | AbbVie has a track record of earnings growth over time. Like AbbVie, Intuitive has a history of earnings growth over time. That's the case for both AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG). |
23,014 | 2022-11-11 00:00:00 UTC | XLV, UNH, ABBV, ELV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/xlv-unh-abbv-elv%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $599.8 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 3... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 4%, AbbVie Inc (Symbol: ABBV) is off about 2.6%, and Elevance Health Inc (Symbol: ELV) is lower by about 5.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 4%, AbbVie Inc (Symbol: ABBV) is off about 2.6%, and Elevance Health Inc (Symbol: ELV) is lower by about 5.9%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one y... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 4%, AbbVie Inc (Symbol: ABBV) is off about 2.6%, and Elevance Health Inc (Symbol: ELV) is lower by about 5.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 4%, AbbVie Inc (Symbol: ABBV) is off about 2.6%, and Elevance Health Inc (Symbol: ELV) is lower by about 5.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... |
23,015 | 2022-11-10 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbvie-4 | null | null | At Holdings Channel, we have reviewed the latest batch of the 28 most recent 13F filings for the 09/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 12 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... | At Holdings Channel, we have reviewed the latest batch of the 28 most recent 13F filings for the 09/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 12 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the ... | At Holdings Channel, we have reviewed the latest batch of the 28 most recent 13F filings for the 09/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 12 of these funds. Existing +12,750 +$948 Steward Partners Investment Advisory LLC Existing +2,489 -$3,046 Executive Wealth Management LLC ... | Existing +12,750 +$948 Steward Partners Investment Advisory LLC Existing +2,489 -$3,046 Executive Wealth Management LLC Existing -1,942 -$343 Legacy Wealth Planning LLC Existing UNCH -$29 Covenant Partners LLC Existing -1,761 -$443 International Assets Investment Management LLC Existing +1,074 -$57 Global Assets Adviso... | At Holdings Channel, we have reviewed the latest batch of the 28 most recent 13F filings for the 09/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 12 of these funds. Boston Partners 6,150,074 4-10 Find out the full Top 10 Hedge Funds Holding ABBV » We'll keep following the latest 13F f... |
23,016 | 2022-11-09 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-54 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Procter & Gamble Company (Symbol: PG) $136.81 $151.67 10.86% AbbVie Inc (Symbol: ABBV) $148.53 $161.94 9.03% Sysco Corp (Symbol: SYY) $83.42 $89.88 7.74% General Dynamics Corp (Symbol: GD) $252.54 $271.18 7.38% Walmart Inc (Symbol: WMT) $142.79 $152.62 6.88% The average 12-month analyst targets are only targets for the... | Procter & Gamble Company (Symbol: PG) $136.81 $151.67 10.86% AbbVie Inc (Symbol: ABBV) $148.53 $161.94 9.03% Sysco Corp (Symbol: SYY) $83.42 $89.88 7.74% General Dynamics Corp (Symbol: GD) $252.54 $271.18 7.38% Walmart Inc (Symbol: WMT) $142.79 $152.62 6.88% The average 12-month analyst targets are only targets for the... | Procter & Gamble Company (Symbol: PG) $136.81 $151.67 10.86% AbbVie Inc (Symbol: ABBV) $148.53 $161.94 9.03% Sysco Corp (Symbol: SYY) $83.42 $89.88 7.74% General Dynamics Corp (Symbol: GD) $252.54 $271.18 7.38% Walmart Inc (Symbol: WMT) $142.79 $152.62 6.88% The average 12-month analyst targets are only targets for the... | Procter & Gamble Company (Symbol: PG) $136.81 $151.67 10.86% AbbVie Inc (Symbol: ABBV) $148.53 $161.94 9.03% Sysco Corp (Symbol: SYY) $83.42 $89.88 7.74% General Dynamics Corp (Symbol: GD) $252.54 $271.18 7.38% Walmart Inc (Symbol: WMT) $142.79 $152.62 6.88% The average 12-month analyst targets are only targets for the... |
23,017 | 2022-11-09 00:00:00 UTC | This Healthcare Stock Disappointed Investors. Here's Why It's Still a Buy. | ABBV | https://www.nasdaq.com/articles/this-healthcare-stock-disappointed-investors.-heres-why-its-still-a-buy. | null | null | AbbVie (NYSE: ABBV) shares have been one of the bright spots in the stock market this year. They're outperforming the S&P 500 index. But the stock has lost a bit of ground since AbbVie's third-quarter earnings report in late October.
The pharmaceutical company noted a slowdown in one of its key businesses -- aesthetics... | All of this may sound grim, but there are positive elements to AbbVie's story that outweigh the negative news, and they're why I still view the stock as a buy. So, AbbVie's progress with Skyrizi and Rinvoq means we should be optimistic about the future of the immunology portfolio -- even considering the inevitable decl... | Skyrizi and Rinvoq sales together represented 15% of AbbVie's total third-quarter revenue. AbbVie (NYSE: ABBV) shares have been one of the bright spots in the stock market this year. But the stock has lost a bit of ground since AbbVie's third-quarter earnings report in late October. | AbbVie (NYSE: ABBV) shares have been one of the bright spots in the stock market this year. Last year, Humira generated more than $20 billion in sales -- about 35% of AbbVie's total revenue. So, AbbVie's progress with Skyrizi and Rinvoq means we should be optimistic about the future of the immunology portfolio -- even ... | Last year, Humira generated more than $20 billion in sales -- about 35% of AbbVie's total revenue. Skyrizi and Rinvoq sales together represented 15% of AbbVie's total third-quarter revenue. AbbVie (NYSE: ABBV) shares have been one of the bright spots in the stock market this year. |
23,018 | 2022-11-09 00:00:00 UTC | If You Like Dividends, You Should Love These 3 Stocks | ABBV | https://www.nasdaq.com/articles/if-you-like-dividends-you-should-love-these-3-stocks-3 | null | null | The growth stock boom of 2021 left some investors wondering if dividend stocks were still prudent holdings to drive long-term returns. Then 2022 came along and answered that concern quite clearly.
Dividend stocks are lynchpins in a diversified portfolio because of their many advantages, including:
Most dividend stocks ... | What helps stabilize AbbVie as an investment is that pharmaceutical companies tend to be safe havens during economic turmoil because medications are generally necessities. And in the current bear market, three dividend stocks -- AbbVie (NYSE: ABBV), VICI Properties (NYSE: VICI), and Texas Instruments (NASDAQ: TXN) -- a... | And in the current bear market, three dividend stocks -- AbbVie (NYSE: ABBV), VICI Properties (NYSE: VICI), and Texas Instruments (NASDAQ: TXN) -- are showing their worth (as seen in the chart below comparing them to the S&P 500). AbbVie defies gravity The major indices all fell into bear territory in 2022 and remain d... | And in the current bear market, three dividend stocks -- AbbVie (NYSE: ABBV), VICI Properties (NYSE: VICI), and Texas Instruments (NASDAQ: TXN) -- are showing their worth (as seen in the chart below comparing them to the S&P 500). AbbVie defies gravity The major indices all fell into bear territory in 2022 and remain d... | The vast majority of individual stocks are down for the year, but AbbVie is not only up for the year but drubbing the S&P 500 by over 30 percentage points in total return. And in the current bear market, three dividend stocks -- AbbVie (NYSE: ABBV), VICI Properties (NYSE: VICI), and Texas Instruments (NASDAQ: TXN) -- a... |
23,019 | 2022-11-08 00:00:00 UTC | Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks | ABBV | https://www.nasdaq.com/articles/investing-%241000-in-the-current-market-dont-overlook-these-2-winning-dividend-stocks | null | null | Dividend stocks are rarely the lightning-growth companies that many investors seem to gravitate toward, but these types of investments certainly have an allure of their own. Whether providing additional capital that you can put back into your portfolio again and again, or increasing your total returns with time, the be... | AbbVie AbbVie (NYSE: ABBV) is a member of the esteemed group of companies known as Dividend Kings, meaning it has increased its dividend annually for at least 50 consecutive years. Since AbbVie was formed, the stock has not only raised its dividend by 270%, but its yield has also increased by more than 20%. Like Bristo... | AbbVie AbbVie (NYSE: ABBV) is a member of the esteemed group of companies known as Dividend Kings, meaning it has increased its dividend annually for at least 50 consecutive years. Since AbbVie was formed, the stock has not only raised its dividend by 270%, but its yield has also increased by more than 20%. Like Bristo... | AbbVie AbbVie (NYSE: ABBV) is a member of the esteemed group of companies known as Dividend Kings, meaning it has increased its dividend annually for at least 50 consecutive years. Since AbbVie was formed, the stock has not only raised its dividend by 270%, but its yield has also increased by more than 20%. Like Bristo... | Since AbbVie was formed, the stock has not only raised its dividend by 270%, but its yield has also increased by more than 20%. AbbVie AbbVie (NYSE: ABBV) is a member of the esteemed group of companies known as Dividend Kings, meaning it has increased its dividend annually for at least 50 consecutive years. Like Bristo... |
23,020 | 2022-11-08 00:00:00 UTC | These 3 Dividend ETFs Are a Retiree's Best Friend | ABBV | https://www.nasdaq.com/articles/these-3-dividend-etfs-are-a-retirees-best-friend-8 | null | null | Dividend exchange-traded funds (ETFs) give income-focused investors an attractive alternative to bonds or stocks, particularly during periods when the latter two are struggling.
Most dividend ETFs invest in a variety of dividend-paying stocks, and many of the most popular ETFs track blue-chip companies with solid divid... | Its top five holdings include ExxonMobil, Chevron, AbbVie, Verizon, and Merck. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Jim Halley has positions in AbbVie. Dividend exchange-traded funds (ETFs) give income-focused investors an attractive alternative to bonds or stocks, particularly during perio... | Its top five holdings include ExxonMobil, Chevron, AbbVie, Verizon, and Merck. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Jim Halley has positions in AbbVie. Keeping an eye on high dividends The iShares Core High Dividend ETF (NYSEMKT: HDV) pays a quarterly dividend of $1.231, offering a current ... | Its top five holdings include ExxonMobil, Chevron, AbbVie, Verizon, and Merck. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Jim Halley has positions in AbbVie. Most dividend ETFs invest in a variety of dividend-paying stocks, and many of the most popular ETFs track blue-chip companies with solid di... | Its top five holdings include ExxonMobil, Chevron, AbbVie, Verizon, and Merck. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Jim Halley has positions in AbbVie. The fund takes the index, excludes the top 5% of the stocks by yield and the top 5% of stocks in each sector by dividend payout ratio, then... |
23,021 | 2022-11-08 00:00:00 UTC | The 7 Best Pharma Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/the-7-best-pharma-stocks-to-buy-now | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting. Two, the best pharma stoc... | The company characterized the sales decline as a “temporary headwind.” And while the impending loss of Humira’s patent protection continues to loom over AbbVie, investors seem happy to kick that can down the street. PFE Pfizer $47.43 MRNA Moderna $169.49 ABBV AbbVie $149.29 JNJ Johnson & Johnson $174.04 LLY Eli Lilly $... | PFE Pfizer $47.43 MRNA Moderna $169.49 ABBV AbbVie $149.29 JNJ Johnson & Johnson $174.04 LLY Eli Lilly $367.68 BNTX BioNTech $160.93 BMY Bristol-Myers Squibb $80.57 Pfizer (PFE) Source: Billion Photos / Shutterstock Covid-19 vaccines have been good to pharmaceutical giant Pfizer (NYSE:PFE). AbbVie (ABBV) Source: Dmitry... | PFE Pfizer $47.43 MRNA Moderna $169.49 ABBV AbbVie $149.29 JNJ Johnson & Johnson $174.04 LLY Eli Lilly $367.68 BNTX BioNTech $160.93 BMY Bristol-Myers Squibb $80.57 Pfizer (PFE) Source: Billion Photos / Shutterstock Covid-19 vaccines have been good to pharmaceutical giant Pfizer (NYSE:PFE). AbbVie (ABBV) Source: Dmitry... | PFE Pfizer $47.43 MRNA Moderna $169.49 ABBV AbbVie $149.29 JNJ Johnson & Johnson $174.04 LLY Eli Lilly $367.68 BNTX BioNTech $160.93 BMY Bristol-Myers Squibb $80.57 Pfizer (PFE) Source: Billion Photos / Shutterstock Covid-19 vaccines have been good to pharmaceutical giant Pfizer (NYSE:PFE). AbbVie (ABBV) Source: Dmitry... |
23,022 | 2022-11-07 00:00:00 UTC | AbbVie : Phase 2 Trial Of AGN-151607 In POAF In Cardiac Surgery Patients Fails To Meet Main Goal | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-phase-2-trial-of-agn-151607-in-poaf-in-cardiac-surgery-patients-fails-to-meet | null | null | (RTTNews) - AbbVie (ABBV) announced results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation in cardiac surgery patients. The primary endpoint of evaluating the occurrence of ... | (RTTNews) - AbbVie (ABBV) announced results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation in cardiac surgery patients. The primary endpoint of evaluating the occurrence of ... | (RTTNews) - AbbVie (ABBV) announced results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation in cardiac surgery patients. The primary endpoint of evaluating the occurrence of ... | (RTTNews) - AbbVie (ABBV) announced results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation in cardiac surgery patients. The primary endpoint of evaluating the occurrence of ... | (RTTNews) - AbbVie (ABBV) announced results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation in cardiac surgery patients. Postoperative atrial fibrillation is the most common ... |
23,023 | 2022-11-05 00:00:00 UTC | 3 Reasons to Buy AbbVie Stock Right Now | ABBV | https://www.nasdaq.com/articles/3-reasons-to-buy-abbvie-stock-right-now | null | null | Despite the market downturn, pharma giant AbbVie (NYSE: ABBV) has performed well this year. The company's shares are up 8% in the past 10 months, easily beating the broader market. But can AbbVie maintain this pace? One of the bears' favorite arguments is that the healthcare company will lose U.S. patent exclusivity fo... | Another important part of AbbVie's strategy to replace Humira has been the rest of the company's immunology lineup: Skyrizi and Rinvoq. Their sales continue to grow rapidly, and AbbVie's CEO, Rick Gonzalez, recently made a bold prediction: "Skyrizi and Rinvoq have established outstanding launch trajectories across exis... | All these factors, combined with AbbVie's dividend and a reasonable valuation, make it an ideal stock for investors to hold on to for a while. Despite the market downturn, pharma giant AbbVie (NYSE: ABBV) has performed well this year. But can AbbVie maintain this pace? | Another important part of AbbVie's strategy to replace Humira has been the rest of the company's immunology lineup: Skyrizi and Rinvoq. Their sales continue to grow rapidly, and AbbVie's CEO, Rick Gonzalez, recently made a bold prediction: "Skyrizi and Rinvoq have established outstanding launch trajectories across exis... | All these factors, combined with AbbVie's dividend and a reasonable valuation, make it an ideal stock for investors to hold on to for a while. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Despite the market downturn, pharma giant AbbVie ... |
23,024 | 2022-11-04 00:00:00 UTC | 3 Dividend Kings Crushing the S&P 500 in 2022 | ABBV | https://www.nasdaq.com/articles/3-dividend-kings-crushing-the-sp-500-in-2022 | null | null | Income investors love to target Dividend Aristocrats, companies that have increased their dividend payouts for a minimum of 25 consecutive years.
However, a step above is the elite Dividend Kings group, companies with at least 50 consecutive years of increased dividend payouts.
Clearly, companies in the Dividend King c... | And several of them have outperformed the S&P 500 by a fair margin in 2022, including AbbVie ABBV, Sysco Corp. SYY, and Johnson & Johnson JNJ. Image Source: Zacks Investment Research AbbVie AbbVie, a global research-based biopharmaceutical company that delivers innovative medicines, became a top pharma company followin... | And all three stocks above – AbbVie ABBV, Sysco Corp. SYY, and Johnson & Johnson JNJ – are Dividend Kings, upping their dividend payouts for a minimum of 50 consecutive years. And several of them have outperformed the S&P 500 by a fair margin in 2022, including AbbVie ABBV, Sysco Corp. SYY, and Johnson & Johnson JNJ. I... | Image Source: Zacks Investment Research AbbVie AbbVie, a global research-based biopharmaceutical company that delivers innovative medicines, became a top pharma company following its acquisition of Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. And all three stocks above – AbbVie ABBV, Sysco... | And all three stocks above – AbbVie ABBV, Sysco Corp. SYY, and Johnson & Johnson JNJ – are Dividend Kings, upping their dividend payouts for a minimum of 50 consecutive years. And several of them have outperformed the S&P 500 by a fair margin in 2022, including AbbVie ABBV, Sysco Corp. SYY, and Johnson & Johnson JNJ. I... |
23,025 | 2022-11-04 00:00:00 UTC | Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows | ABBV | https://www.nasdaq.com/articles/ironwoods-irwd-q3-earnings-beat-linzess-volume-grows | null | null | Ironwood Pharmaceuticals, Inc. IRWD reported adjusted earnings of 28 cents per share in third-quarter 2022, beating the Zacks Consensus Estimate of 27 cents. The company reported adjusted earnings of 33 cents per share in the year-ago quarter.
Total revenues of $109 million missed the Zacks Consensus Estimate of $112 m... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $261.13 million in the United States, up 3.4% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or l... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $261.13 million in the United States, up 3.4% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or l... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $261.13 million in the United States, up 3.4% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or l... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $261.13 million in the United States, up 3.4% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or l... |
23,026 | 2022-11-04 00:00:00 UTC | Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View | ABBV | https://www.nasdaq.com/articles/amgen-amgn-beats-on-q3-earnings-sales-tweaks-2022-view | null | null | Amgen AMGN reported third-quarter 2022 earnings of $4.70 per share, which beat the Zacks Consensus Estimate of $4.43 as well as our estimate of $4.37 per share. Earnings rose 15% year over year. Lower operating expenses and share count boosted earnings in the quarter.
Total revenues of $6.65 billion also beat the Zacks... | Amgevita (biosimilar of AbbVie’s [ABBV] Humira) sales were $117 million in the quarter, up 5% year over year, driven by volume growth, which was partially offset by currency headwinds and lower net selling price due to increased competitive pressure. Amgen will be one of the first companies to launch its biosimilar of ... | Amgevita (biosimilar of AbbVie’s [ABBV] Humira) sales were $117 million in the quarter, up 5% year over year, driven by volume growth, which was partially offset by currency headwinds and lower net selling price due to increased competitive pressure. Amgen will be one of the first companies to launch its biosimilar of ... | Amgevita (biosimilar of AbbVie’s [ABBV] Humira) sales were $117 million in the quarter, up 5% year over year, driven by volume growth, which was partially offset by currency headwinds and lower net selling price due to increased competitive pressure. Amgen will be one of the first companies to launch its biosimilar of ... | Amgevita (biosimilar of AbbVie’s [ABBV] Humira) sales were $117 million in the quarter, up 5% year over year, driven by volume growth, which was partially offset by currency headwinds and lower net selling price due to increased competitive pressure. Amgen will be one of the first companies to launch its biosimilar of ... |
23,027 | 2022-11-04 00:00:00 UTC | 2 Dividend Growth Stocks to Buy and Hold for Years | ABBV | https://www.nasdaq.com/articles/2-dividend-growth-stocks-to-buy-and-hold-for-years | null | null | Did you know that a stock which increases its dividend by 7% will double its payout in a decade? That's the power of investing in dividend growth stocks. Over time, their yields will rise and investors can earn much more on their initial investment. That can make a low-yielding stock look deceptively low.
Two stocks th... | AbbVie's broad portfolio of assets that cover immunology, oncology, aesthetics, neuroscience, and eye care makes this a safe stock to own for the long term. Two stocks that have been aggressively increasing their dividends in recent years are AbbVie (NYSE: ABBV) and Visa (NYSE: V). AbbVie Drugmaker AbbVie generated mor... | Two stocks that have been aggressively increasing their dividends in recent years are AbbVie (NYSE: ABBV) and Visa (NYSE: V). With strong fundamentals, a diverse business, and a great dividend, AbbVie makes for a solid stock to buy and hold. AbbVie Drugmaker AbbVie generated more than $56 billion in revenue last year a... | Two stocks that have been aggressively increasing their dividends in recent years are AbbVie (NYSE: ABBV) and Visa (NYSE: V). With strong fundamentals, a diverse business, and a great dividend, AbbVie makes for a solid stock to buy and hold. AbbVie Drugmaker AbbVie generated more than $56 billion in revenue last year a... | AbbVie Drugmaker AbbVie generated more than $56 billion in revenue last year and had over $11 billion in profit. Two stocks that have been aggressively increasing their dividends in recent years are AbbVie (NYSE: ABBV) and Visa (NYSE: V). AbbVie's broad portfolio of assets that cover immunology, oncology, aesthetics, n... |
23,028 | 2022-11-04 00:00:00 UTC | Better Buy: AbbVie vs. Walgreens Boots Alliance | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-walgreens-boots-alliance | null | null | Whether you're looking for passive income or for growth, both AbbVie (NYSE: ABBV) and Walgreens Boots Alliance (NASDAQ: WBA) might be of interest. The pair pay decent dividends, operate with business models that are proven to be sustainable over time, and aren't in deep danger of running afoul of longstanding economic ... | Whether you're looking for passive income or for growth, both AbbVie (NYSE: ABBV) and Walgreens Boots Alliance (NASDAQ: WBA) might be of interest. But there's no way that a pharmaceutical juggernaut like AbbVie and a massive pharmacy chain like Walgreens could be equal in terms of their future potential. AbbVie's rolli... | AbbVie's rolling drug launches continue to pay off The primary reason to invest in AbbVie is that its drug development pipeline is a powerful growth engine that's not going to slacken anytime soon. Walgreens moves into providing healthcare directly Walgreens' appeal to investors, its dividend, is entirely different tha... | AbbVie's rolling drug launches continue to pay off The primary reason to invest in AbbVie is that its drug development pipeline is a powerful growth engine that's not going to slacken anytime soon. Walgreens moves into providing healthcare directly Walgreens' appeal to investors, its dividend, is entirely different tha... | Whether you're looking for passive income or for growth, both AbbVie (NYSE: ABBV) and Walgreens Boots Alliance (NASDAQ: WBA) might be of interest. But there's no way that a pharmaceutical juggernaut like AbbVie and a massive pharmacy chain like Walgreens could be equal in terms of their future potential. AbbVie's rolli... |
23,029 | 2022-11-04 00:00:00 UTC | 3 Top Healthcare Stocks to Buy for November | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-for-november | null | null | The end of the year is right around the corner. But this time of year actually is a beginning for certain healthcare stocks. That's because important share-performance catalysts and/or revenue opportunities lie just ahead. And that's why these players make great buys in November.
CRISPR Therapeutics (NASDAQ: CRSP) is s... | But here's the good news: AbbVie's two younger immunology drugs, Skyrizi and Rinvoq, together may eventually surpass Humira's peak sales. And sales are multiplying for AbbVie's (NYSE: ABBV) two key immunology drugs. AbbVie Let's talk about the bad news first: AbbVie's super-blockbuster immunology drug Humira is set to ... | But here's the good news: AbbVie's two younger immunology drugs, Skyrizi and Rinvoq, together may eventually surpass Humira's peak sales. And sales are multiplying for AbbVie's (NYSE: ABBV) two key immunology drugs. AbbVie Let's talk about the bad news first: AbbVie's super-blockbuster immunology drug Humira is set to ... | AbbVie Let's talk about the bad news first: AbbVie's super-blockbuster immunology drug Humira is set to lose exclusivity next year. And sales are multiplying for AbbVie's (NYSE: ABBV) two key immunology drugs. But here's the good news: AbbVie's two younger immunology drugs, Skyrizi and Rinvoq, together may eventually s... | Another key growth area for AbbVie lies in aesthetics. And sales are multiplying for AbbVie's (NYSE: ABBV) two key immunology drugs. AbbVie Let's talk about the bad news first: AbbVie's super-blockbuster immunology drug Humira is set to lose exclusivity next year. |
23,030 | 2022-11-02 00:00:00 UTC | 3 Year-End Investing Strategies You Should Consider Right Now | ABBV | https://www.nasdaq.com/articles/3-year-end-investing-strategies-you-should-consider-right-now | null | null | In a perfect world, the calendar wouldn't matter when it comes to investing. Companies would always be fairly valued based on their future prospects, and major price swings would be rare events driven by substantial changes to those prospects. In the real world, however, the calendar matters. Investors make decisions o... | For example, in the healthcare sector, AbbVie is a $260 billion industry giant with a yield above 4%. In this category, there are names like Apple and MGM Resorts International, a casino operator that's pushing into the high potential online and mobile betting segment. For any stocks where your investing thesis no long... | For example, in the healthcare sector, AbbVie is a $260 billion industry giant with a yield above 4%. It pays to buy a payer Eric Volkman: The end of the year is a time when a great many companies declare dividend raises. It's time to go bargain hunting Chuck Saletta: The tax-loss harvesting strategy Parkev outlines ab... | For example, in the healthcare sector, AbbVie is a $260 billion industry giant with a yield above 4%. Investors can make the best of a down year in 2022 Parkev Tatevosian: As the end of a challenging year for the market approaches, there is one strategy that makes the best of this situation. For any stocks where your i... | For example, in the healthcare sector, AbbVie is a $260 billion industry giant with a yield above 4%. Investors make decisions on factors like which tax year an investment choice will impact or whether or not a sale qualifies for long-term capital gains tax treatment. Investors can make the best of a down year in 2022 ... |
23,031 | 2022-11-02 00:00:00 UTC | Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever | ABBV | https://www.nasdaq.com/articles/got-%245000-buy-these-3-dividend-kings-and-hold-them-forever | null | null | Whether you're looking to make some extra dough from dividend income or build defensive investments into your portfolio, Dividend Kings are stocks you should know about these days. What they all have in common is this: they've raised their dividends for at least 50 (yup, 50) consecutive years.
The capacity to build suc... | AbbVie As the maker of Humira, one of the top-grossing drugs of all time, AbbVie (NYSE: ABBV) is practically a money printer with free cash flow topping $21.9 billion in 2021. In 2023 alone, AbbVie could see as many as eight of its programs get approved by regulators, and with a myriad of oncology and immunology candid... | AbbVie As the maker of Humira, one of the top-grossing drugs of all time, AbbVie (NYSE: ABBV) is practically a money printer with free cash flow topping $21.9 billion in 2021. In 2023 alone, AbbVie could see as many as eight of its programs get approved by regulators, and with a myriad of oncology and immunology candid... | AbbVie As the maker of Humira, one of the top-grossing drugs of all time, AbbVie (NYSE: ABBV) is practically a money printer with free cash flow topping $21.9 billion in 2021. In 2023 alone, AbbVie could see as many as eight of its programs get approved by regulators, and with a myriad of oncology and immunology candid... | AbbVie As the maker of Humira, one of the top-grossing drugs of all time, AbbVie (NYSE: ABBV) is practically a money printer with free cash flow topping $21.9 billion in 2021. In 2023 alone, AbbVie could see as many as eight of its programs get approved by regulators, and with a myriad of oncology and immunology candid... |
23,032 | 2022-11-02 00:00:00 UTC | 5 Stocks to Watch on Recent Dividend Hikes Amid High Volatility | ABBV | https://www.nasdaq.com/articles/5-stocks-to-watch-on-recent-dividend-hikes-amid-high-volatility | null | null | Major U.S indexes like the S&P 500, the Dow and the Nasdaq continued to gyrate in the month of October after a disappointing this year till September. Though the stock market recovered in October, the overall sentiment of investors remains cautious ahead of the Federal Reserve’s meeting this week.
The Fed is expected ... | On that note, let us look at companies like AbbVie ABBV, Astec Industries ASTE, Boise Cascade BCC, Esquire Financial ESQ and The Hartford Financial Services Group HIG that have lately hiked their dividend payments. AbbVie is a North Chicago, IL-based company that discovers, develops, manufactures and sells pharmaceutic... | On that note, let us look at companies like AbbVie ABBV, Astec Industries ASTE, Boise Cascade BCC, Esquire Financial ESQ and The Hartford Financial Services Group HIG that have lately hiked their dividend payments. AbbVie is a North Chicago, IL-based company that discovers, develops, manufactures and sells pharmaceutic... | On that note, let us look at companies like AbbVie ABBV, Astec Industries ASTE, Boise Cascade BCC, Esquire Financial ESQ and The Hartford Financial Services Group HIG that have lately hiked their dividend payments. AbbVie is a North Chicago, IL-based company that discovers, develops, manufactures and sells pharmaceutic... | On that note, let us look at companies like AbbVie ABBV, Astec Industries ASTE, Boise Cascade BCC, Esquire Financial ESQ and The Hartford Financial Services Group HIG that have lately hiked their dividend payments. ABBV currently carries a Zacks Rank #3 (Hold). AbbVie is a North Chicago, IL-based company that discovers... |
23,033 | 2022-11-01 00:00:00 UTC | CVS, Walmart, Walgreens agree to pay $13.8 bln to settle U.S. opioid claims - sources | ABBV | https://www.nasdaq.com/articles/cvs-walmart-walgreens-agree-to-pay-%2413.8-bln-to-settle-u.s.-opioid-claims-sources | null | null | By Brendan Pierson
Nov 1 (Reuters) - CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N have tentatively agreed to pay about $13.8 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, according to two people familiar with... | By Brendan Pierson Nov 1 (Reuters) - CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N have tentatively agreed to pay about $13.8 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, according to two people familiar with... | By Brendan Pierson Nov 1 (Reuters) - CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N have tentatively agreed to pay about $13.8 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, according to two people familiar with... | By Brendan Pierson Nov 1 (Reuters) - CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N have tentatively agreed to pay about $13.8 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, according to two people familiar with... | By Brendan Pierson Nov 1 (Reuters) - CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N have tentatively agreed to pay about $13.8 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, according to two people familiar with... |
23,034 | 2022-11-01 00:00:00 UTC | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-1 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned +5.8% over the past month versus the Zacks S&P 500 composite's +8.1% change. The Zacks ... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie b... | Last Reported Results and Surprise History AbbVie reported revenues of $14.81 billion in the last reported quarter, representing a year-over-year change of +3.3%. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gain... | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 9.6% over this period. AbbVie is expected to post earnings of $3.72 per share for the current quarter, representing a year-over-year change of +12.4%. | For the next fiscal year, the consensus earnings estimate of $11.47 indicates a change of -17.4% from what AbbVie is expected to report a year ago. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 9.6% over th... |
23,035 | 2022-11-01 00:00:00 UTC | These 2 Passive Income Stars Just Declared Dividend Raises | ABBV | https://www.nasdaq.com/articles/these-2-passive-income-stars-just-declared-dividend-raises | null | null | Investors are now in the midst of the final earnings season of 2022. Companies often cap their reporting year with a dividend raise, and the raising has been relatively brisk lately. Businesses of every size and in every sector are adding to their payouts.
Two giants in their respective industries, AbbVie (NYSE: ABBV) ... | AbbVie is the company behind Humira, the blockbuster treatment for rheumatoid arthritis and a set of other afflictions whose sales approached a staggering $20 billion-plus last year. Two giants in their respective industries, AbbVie (NYSE: ABBV) and Visa (NYSE: V), are among that group of lifters. AbbVie Being the deve... | Visa Although Visa's dividend growth streak isn't as lengthy as AbbVie's and its yield is notably lower, Visa is still a reliable payer and lifter. Two giants in their respective industries, AbbVie (NYSE: ABBV) and Visa (NYSE: V), are among that group of lifters. AbbVie Being the developer of the world's top-selling dr... | With a number like that from one drug alone, it's no wonder AbbVie is generous with its distribution; in fact, it's one of the stock market's rare Dividend Kings with a five-decade streak behind it. Visa Although Visa's dividend growth streak isn't as lengthy as AbbVie's and its yield is notably lower, Visa is still a ... | Visa Although Visa's dividend growth streak isn't as lengthy as AbbVie's and its yield is notably lower, Visa is still a reliable payer and lifter. Two giants in their respective industries, AbbVie (NYSE: ABBV) and Visa (NYSE: V), are among that group of lifters. AbbVie Being the developer of the world's top-selling dr... |
23,036 | 2022-11-01 00:00:00 UTC | 3 Dividend Stocks to Buy Hand Over Fist in November | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-hand-over-fist-in-november | null | null | There's just something comforting about a stock that pays you to own it. That's especially the case amid the current overall stock market volatility.
I'm talking, of course, about dividend stocks. Well over 4,000 stocks traded on U.S. exchanges offer dividends. But some are better than others. Here are three dividend s... | AbbVie Perhaps the most important thing to know about AbbVie (NYSE: ABBV) is that it's a Dividend King. AbbVie's streak of dividend hikes now stands at 51 years in a row after the company's latest dividend increase was announced last week. But sales for AbbVie's top-selling drug, Humira, are about to decline with biosi... | See the 10 stocks *Stock Advisor returns as of September 30, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie Perhaps the most important thing to know about AbbVie (NYSE: ABBV) is that it's a Dividend King. AbbVie's streak o... | See the 10 stocks *Stock Advisor returns as of September 30, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie Perhaps the most important thing to know about AbbVie (NYSE: ABBV) is that it's a Dividend King. AbbVie's streak o... | Next year will likely be the trough year for AbbVie's earnings. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie Perhaps the most important thing to know about Abb... |
23,037 | 2022-10-28 00:00:00 UTC | Daily Dividend Report: AAPL,BKR,ABBV,ROK,WBA | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-aaplbkrabbvrokwba | null | null | Apple's board of directors has declared a cash dividend of $0.23 per share of the Company's common stock. The dividend is payable on November 10, 2022 to shareholders of record as of the close of business on November 7, 2022.
Baker Hughes announced today that the Baker Hughes Board of Directors declared an increased qu... | This reflects an increase of approximately 5.0 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.41 per share to $1.48 per share beginni... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.41 per share to $1.48 per share beginning with the dividend payable on February 15, 2023 to shareholders of record as of January 13, 2023. This reflects an increase of approximately 5.0 percent, ... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.41 per share to $1.48 per share beginning with the dividend payable on February 15, 2023 to shareholders of record as of January 13, 2023. This reflects an increase of approximately 5.0 percent, ... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.41 per share to $1.48 per share beginning with the dividend payable on February 15, 2023 to shareholders of record as of January 13, 2023. This reflects an increase of approximately 5.0 percent, ... |
23,038 | 2022-10-28 00:00:00 UTC | AbbVie (ABBV) Q3 2022 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-2022-earnings-call-transcript | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q3 2022 Earnings Call
Oct 28, 2022, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie's third quarter 2022earnings conference call [Operator ins... | We remain very excited about the long-term potential for Skyrizi and Rinvoq which are already having a significant impact on AbbVie's growth and performance, contributing approximately $2.1 billion in combined sales this quarter, representing nearly 15% of total company net revenues. AbbVie (NYSE: ABBV) Q3 2022 Earning... | Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Jeff Stewart -- Executive Vice President, Chief Commercial Officer Tom Hudson -- Senior Vice President, Research and Development and Chief Scientific Of... | Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Jeff Stewart -- Executive Vice President, Chief Commercial Officer Tom Hudson -- Senior Vice President, Research and Development and Chief Scientific Of... | Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Jeff Stewart -- Executive Vice President, Chief Commercial Officer Tom Hudson -- Senior Vice President, Research and Development and Chief Scientific Of... |
23,039 | 2022-10-28 00:00:00 UTC | Friday's ETF with Unusual Volume: DEF | ABBV | https://www.nasdaq.com/articles/fridays-etf-with-unusual-volume%3A-def | null | null | The Invesco Defensive Equity ETF is seeing unusually high volume in afternoon trading Friday, with over 136,000 shares traded versus three month average volume of about 25,000. Shares of DEF were up about 2% on the day.
Components of that ETF with the highest volume on Friday were Gilead Sciences, trading up about 11.3... | Abbvie is lagging other components of the Invesco Defensive Equity ETF Friday, trading lower by about 4.4%. The Invesco Defensive Equity ETF is seeing unusually high volume in afternoon trading Friday, with over 136,000 shares traded versus three month average volume of about 25,000. Components of that ETF with the hig... | Abbvie is lagging other components of the Invesco Defensive Equity ETF Friday, trading lower by about 4.4%. The Invesco Defensive Equity ETF is seeing unusually high volume in afternoon trading Friday, with over 136,000 shares traded versus three month average volume of about 25,000. VIDEO: Friday's ETF with Unusual Vo... | Abbvie is lagging other components of the Invesco Defensive Equity ETF Friday, trading lower by about 4.4%. The Invesco Defensive Equity ETF is seeing unusually high volume in afternoon trading Friday, with over 136,000 shares traded versus three month average volume of about 25,000. Components of that ETF with the hig... | Abbvie is lagging other components of the Invesco Defensive Equity ETF Friday, trading lower by about 4.4%. The Invesco Defensive Equity ETF is seeing unusually high volume in afternoon trading Friday, with over 136,000 shares traded versus three month average volume of about 25,000. Shares of DEF were up about 2% on t... |
23,040 | 2022-10-28 00:00:00 UTC | AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-beats-on-q3-earnings-lags-sales-narrows-22-view | null | null | AbbVie Inc. ABBV reported earnings of $3.66 per share for the third quarter of 2022, beating both the Zacks Consensus Estimate and our estimate of $3.56 and $3.57, respectively. The reported earnings also exceeded the guidance of $3.55-$3.59. Earnings rose 29.3% year over year.
ABBV’s revenues of $14.81 billion missed ... | ABBV’s leukemia drug Venclexta generated revenues of $515 million in the reported quarter, reflecting 11.3% year-over-year growth on an operational basis. Juvederm sales were hurt by the impact of COVID in China and the suspension of AbbVie’s aesthetics business operations in Russia, a key market for fillers. AbbVie In... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 9.9% on an operational basis to $1.65 billion in the quarter, as growth of Venclexta sales, was more than offset by lower U.S. sales of Imbruvica. Image Source: Zacks Investment Research AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quo... | Sales of AbbVie’s oral migraine drug Ubrelvy generated $160 million of revenues, down 1.2% on an operational basis year over year. AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 9.9% on an operational basis to $1.65 billion in the quarter, as growth of Venclexta sales, was more than off... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 9.9% on an operational basis to $1.65 billion in the quarter, as growth of Venclexta sales, was more than offset by lower U.S. sales of Imbruvica. AbbVie Inc. ABBV reported earnings of $3.66 per share for the third quarter of 2022, beating ... |
23,041 | 2022-10-28 00:00:00 UTC | AbbVie Says EMA Validates MAA For Epcoritamab To Treat Relapsed/refractory Diffuse Large B-cell | ABBV | https://www.nasdaq.com/articles/abbvie-says-ema-validates-maa-for-epcoritamab-to-treat-relapsed-refractory-diffuse-large-b | null | null | (RTTNews) - AbbVie (ABBV) announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell l... | (RTTNews) - AbbVie (ABBV) announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell l... | (RTTNews) - AbbVie (ABBV) announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell l... | (RTTNews) - AbbVie (ABBV) announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell l... | (RTTNews) - AbbVie (ABBV) announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell l... |
23,042 | 2022-10-28 00:00:00 UTC | AbbVie (ABBV) Q3 Earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-beat-estimates | null | null | AbbVie (ABBV) came out with quarterly earnings of $3.66 per share, beating the Zacks Consensus Estimate of $3.56 per share. This compares to earnings of $3.33 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 2.81%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $3.66 per share, beating the Zacks Consensus Estimate of $3.56 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.81 billion for the quarter ended September 2022, missing the Zacks Consensus Estimate by 0.74%. AbbVie... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.81 billion for the quarter ended September 2022, missing the Zacks Consensus Estimate by 0.74%. AbbVie (ABBV) came out with quarterly earnings of $3.66 per share, beating the Zacks Consensus Estimate of $3.56 per share. AbbVie... | AbbVie (ABBV) came out with quarterly earnings of $3.66 per share, beating the Zacks Consensus Estimate of $3.56 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.81 billion for the quarter ended September 2022, missing the Zacks Consensus Estimate by 0.74%. AbbVie... | AbbVie (ABBV) came out with quarterly earnings of $3.66 per share, beating the Zacks Consensus Estimate of $3.56 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.81 billion for the quarter ended September 2022, missing the Zacks Consensus Estimate by 0.74%. AbbVie... |
23,043 | 2022-10-28 00:00:00 UTC | AbbVie Q3 22 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q3-22-earnings-conference-call-at-9%3A00-am-et | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 28, 2022, to discuss Q3 22 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 28, 2022, to discuss Q3 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 28, 2022, to discuss Q3 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 28, 2022, to discuss Q3 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 28, 2022, to discuss Q3 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... |
23,044 | 2022-10-28 00:00:00 UTC | AbbVie Q3 Profit Increases, beats estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q3-profit-increases-beats-estimates | null | null | (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that increased from last year and beat the Street estimates.
The company's earnings came in at $3.949 billion, or $2.21 per share. This compares with $3.179 billion, or $1.78 per share, in last year's third quarter.
Excluding items, AbbVie reported adjus... | (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that increased from last year and beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $6.528 billion or $3.66 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q3): $3.949 Bln. | Excluding items, AbbVie reported adjusted earnings of $6.528 billion or $3.66 per share for the period. (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that increased from last year and beat the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q3): $3.949 Bln. | (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that increased from last year and beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $6.528 billion or $3.66 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q3): $3.949 Bln. | Excluding items, AbbVie reported adjusted earnings of $6.528 billion or $3.66 per share for the period. (RTTNews) - AbbVie (ABBV) released earnings for its third quarter that increased from last year and beat the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q3): $3.949 Bln. |
23,045 | 2022-10-28 00:00:00 UTC | Health Care Sector Update for 10/28/2022: DVA, ABBV, SNY, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-10-28-2022%3A-dva-abbv-sny-xlv-ibb | null | null | Health care stocks were flat to lower premarket Friday. The Health Care SPDR (XLV) was flat and the iShares Biotechnology Index (IBB) was recently inactive.
DaVita (DVA) was down more than 18% after it reported Q3 adjusted earnings of $1.45 per diluted share, down from $2.36 a year earlier. Analysts polled by Yahoo! Fi... | AbbVie (ABBV) reported Q3 adjusted diluted earnings of $3.66, up from $2.83 last year. AbbVie was almost 4% lower recently. The Health Care SPDR (XLV) was flat and the iShares Biotechnology Index (IBB) was recently inactive. | AbbVie (ABBV) reported Q3 adjusted diluted earnings of $3.66, up from $2.83 last year. AbbVie was almost 4% lower recently. Analysts polled by Capital IQ expected $3.56. | AbbVie (ABBV) reported Q3 adjusted diluted earnings of $3.66, up from $2.83 last year. AbbVie was almost 4% lower recently. The Health Care SPDR (XLV) was flat and the iShares Biotechnology Index (IBB) was recently inactive. | AbbVie was almost 4% lower recently. AbbVie (ABBV) reported Q3 adjusted diluted earnings of $3.66, up from $2.83 last year. Analysts polled by Capital IQ expected $3.56. |
23,046 | 2022-10-27 00:00:00 UTC | Pfizer Earnings Preview: Growth & Diversification is Key | ABBV | https://www.nasdaq.com/articles/pfizer-earnings-preview%3A-growth-diversification-is-key | null | null | Pfizer’s PFE Q3 earnings report on November 1 will give insight into the company’s ability to sustain growth from its Covid-19 vaccines. Vaccinations gave PFE a boost during the pandemic with the stock up nicely over the last few years.
Post-pandemic, revenue from Covid-19 vaccines may eventually start to fade and inve... | Performance & Valuation PFE is down -22% in 2022 to roughly match the S&P 500’s decline while underperforming its peer group’s +1% which includes notable companies like Johnson & Johnson JNJ and AbbVie ABBV. AbbVie Inc. (ABBV): Free Stock Analysis Report When including dividends over the last 5 years, PFE’s total retur... | Performance & Valuation PFE is down -22% in 2022 to roughly match the S&P 500’s decline while underperforming its peer group’s +1% which includes notable companies like Johnson & Johnson JNJ and AbbVie ABBV. AbbVie Inc. (ABBV): Free Stock Analysis Report Image Source: Zacks Investment Research Business Units Pfizer’s b... | Performance & Valuation PFE is down -22% in 2022 to roughly match the S&P 500’s decline while underperforming its peer group’s +1% which includes notable companies like Johnson & Johnson JNJ and AbbVie ABBV. AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer’s PFE Q3 earnings report on November 1 will give insight i... | Performance & Valuation PFE is down -22% in 2022 to roughly match the S&P 500’s decline while underperforming its peer group’s +1% which includes notable companies like Johnson & Johnson JNJ and AbbVie ABBV. AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer beat on both its top and bottom lines during Q2 and blaste... |
23,047 | 2022-10-27 00:00:00 UTC | AbbVie Q3 Preview: Can Shares Continue Their Run? | ABBV | https://www.nasdaq.com/articles/abbvie-q3-preview%3A-can-shares-continue-their-run | null | null | The Zacks Medical sector has performed slightly better than the S&P 500 YTD, down 18.7% vs. the general market’s roughly 20% decline.
A titan in the realm, AbbVie ABBV, is on deck to unveil Q3 earnings on October 28th, before the market open.
AbbVie enjoys leadership positions in key therapeutic areas, including immuno... | AbbVie enjoys leadership positions in key therapeutic areas, including immunology, hematologic oncology, neuroscience, aesthetics, eye care, and women’s health. Image Source: Zacks Investment Research The relative strength ABBV shares have displayed is undoubtedly a highlight in a historically-volatile 2022, indicating... | Image Source: Zacks Investment Research AbbVie’s top-line also appears to be in solid standing; the Zacks Consensus Sales Estimate of $14.9 billion suggests revenue growth of roughly 4% from year-ago quarterly sales of $14.3 billion. A titan in the realm, AbbVie ABBV, is on deck to unveil Q3 earnings on October 28th, b... | Image Source: Zacks Investment Research AbbVie’s top-line also appears to be in solid standing; the Zacks Consensus Sales Estimate of $14.9 billion suggests revenue growth of roughly 4% from year-ago quarterly sales of $14.3 billion. A titan in the realm, AbbVie ABBV, is on deck to unveil Q3 earnings on October 28th, b... | A titan in the realm, AbbVie ABBV, is on deck to unveil Q3 earnings on October 28th, before the market open. AbbVie enjoys leadership positions in key therapeutic areas, including immunology, hematologic oncology, neuroscience, aesthetics, eye care, and women’s health. Share Performance & Valuation AbbVie shares have b... |
23,048 | 2022-10-27 00:00:00 UTC | Pre-Market Earnings Report for October 28, 2022 : XOM, CVX, ABBV, NEE, SNY, CL, AON, CHTR, IMO, GWW, LYB, CHD | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-october-28-2022-%3A-xom-cvx-abbv-nee-sny-cl-aon-chtr-imo-0 | null | null | The following companies are expected to report earnings prior to market open on 10/28/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending September 30, 2022. The oil company's consensus earnings per share forecast from the 9 ... | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.85 vs. an industry ratio of 15.70. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.85 vs. an industry ratio of 15.70. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.85 vs. an industry ratio of 15.70. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2022. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.85 vs. an industry ratio of 15.70. |
23,049 | 2022-10-27 00:00:00 UTC | Pre-Market Earnings Report for October 28, 2022 : XOM, CVX, ABBV, NEE, SNY, CL, AON, CHTR, IMO, GWW, LYB, CHD | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-october-28-2022-%3A-xom-cvx-abbv-nee-sny-cl-aon-chtr-imo-gww | null | null | The following companies are expected to report earnings prior to market open on 10/28/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending September 30, 2022. The oil company's consensus earnings per share forecast from the 9 ... | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.85 vs. an industry ratio of 15.70. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.85 vs. an industry ratio of 15.70. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.85 vs. an industry ratio of 15.70. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2022. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.85 vs. an industry ratio of 15.70. |
23,050 | 2022-10-27 00:00:00 UTC | XLV, ABBV, ELV, MDT: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/xlv-abbv-elv-mdt%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $203.8 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 2... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is up about 0.2%, and Medtronic PLC (Symbol: MDT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF C... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is up about 0.2%, and Medtronic PLC (Symbol: MDT) is higher by about 0.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year pric... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is up about 0.2%, and Medtronic PLC (Symbol: MDT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF C... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is up about 0.2%, and Medtronic PLC (Symbol: MDT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF C... |
23,051 | 2022-10-26 00:00:00 UTC | 2 Monster Stocks to Buy Without Any Hesitation | ABBV | https://www.nasdaq.com/articles/2-monster-stocks-to-buy-without-any-hesitation-6 | null | null | Hesitation. That's a key word in the investment community right now. Many investors are hesitating before buying stocks. This bear market isn't over. And investors worry even the strongest stocks may fall further. That's as problems such as higher inflation weigh on companies and their customers.
It's important to reme... | AbbVie's Botox for migraine and Vraylar for bipolar disorder also produced double-digit revenue growth in the quarter -- leading gains in neuroscience. AbbVie AbbVie (NYSE: ABBV) sells treatments in a variety of high-growth areas, including immunology and neuroscience. Now the bad news is AbbVie's major blockbuster Hum... | Even considering AbbVie's share gains, the stock still is trading at only about 10 times forward earnings estimates. AbbVie AbbVie (NYSE: ABBV) sells treatments in a variety of high-growth areas, including immunology and neuroscience. Now the bad news is AbbVie's major blockbuster Humira will face competition next year... | ABBV Revenue (Annual) data by YCharts The products mentioned here -- and the company's dozens of pipeline candidates across treatment areas -- are reasons to be optimistic about future revenue. AbbVie AbbVie (NYSE: ABBV) sells treatments in a variety of high-growth areas, including immunology and neuroscience. Now the ... | AbbVie AbbVie (NYSE: ABBV) sells treatments in a variety of high-growth areas, including immunology and neuroscience. Now the bad news is AbbVie's major blockbuster Humira will face competition next year. But AbbVie is set to manage this situation. |
23,052 | 2022-10-26 00:00:00 UTC | Will Merck Stock Rise After Its Q3 Results? | ABBV | https://www.nasdaq.com/articles/will-merck-stock-rise-after-its-q3-results | null | null | Merck (NYSE: MRK) is scheduled to report its Q3 2022 results on Thursday, October 27. We expect the company to post mixed results, with revenue falling short and earnings slightly above the consensus estimate. Although the company should benefit from continued market share gains for Keytruda and Gardasil, among other p... | We expect the company to post mixed results, with revenue falling short and earnings slightly above the consensus estimate. Although the company should benefit from continued market share gains for Keytruda and Gardasil, among other products, forex headwinds may weigh on its overall performance. This represents a forwa... | (1) Revenues expected to be below the consensus estimates Trefis estimates Merck’s Q3 2022 revenues to be $13.9 billion, reflecting mid-single-digit y-o-y growth but below the $14.1 billion consensus estimate. Looking at Q2 2022, Merck reported revenue of $14.6 billion, reflecting a significant 28% y-o-y growth, partly... | (1) Revenues expected to be below the consensus estimates Trefis estimates Merck’s Q3 2022 revenues to be $13.9 billion, reflecting mid-single-digit y-o-y growth but below the $14.1 billion consensus estimate. (2) EPS expected to be slightly above the consensus estimates Merck’s Q3 2022 adjusted earnings per share (EPS... | We expect MRK stock to trade sideways post-Q3 and find it fairly valued at its current levels, as discussed below. (3) MRK stock is fairly valued We estimate Merck’s Valuation to be $102 per share, which is only 7% above the current market price of $96. Total [2] MRK Return 11% 25% 63% S&P 500 Return 5% -21% 68% Trefis... |
23,053 | 2022-10-25 00:00:00 UTC | Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth | ABBV | https://www.nasdaq.com/articles/pfizer-pfe-reports-next-week%3A-wall-street-expects-earnings-growth-1 | null | null | Pfizer (PFE) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor t... | An Industry Player's Expected Results AbbVie (ABBV), another stock in the Zacks Large Cap Pharmaceuticals industry, is expected to report earnings per share of $3.56 for the quarter ended September 2022. The consensus EPS estimate for AbbVie has been revised 0.1% lower over the last 30 days to the current level. When c... | When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate. An Industry Player's Expected Results AbbVie (ABBV), another stock in the Zacks Large Cap Pharmaceuticals industry, is expected to report earnings per share of $3.... | An Industry Player's Expected Results AbbVie (ABBV), another stock in the Zacks Large Cap Pharmaceuticals industry, is expected to report earnings per share of $3.56 for the quarter ended September 2022. The consensus EPS estimate for AbbVie has been revised 0.1% lower over the last 30 days to the current level. When c... | When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate. An Industry Player's Expected Results AbbVie (ABBV), another stock in the Zacks Large Cap Pharmaceuticals industry, is expected to report earnings per share of $3.... |
23,054 | 2022-10-25 00:00:00 UTC | 3 Top Dividend Stocks to Buy and Hold in 2023 | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-to-buy-and-hold-in-2023 | null | null | Three words can make you a lot of money over the long run. What are those three words? Dividends, buy, and hold.
Dividends made up over half of the S&P 500's total return since 1990. Following a buy-and-hold strategy would have prevented you from locking in significant losses during the sell-offs of 2001, 2008, and 202... | More importantly, AbbVie's slump shouldn't last very long: The company projects that it will return to sustained revenue growth quickly. AbbVie AbbVie (NYSE: ABBV) isn't just an ordinary dividend stock; it's a member of dividend royalty. AbbVie has raised its dividend payout by more than 250% since spinning off from Ab... | See the 10 stocks *Stock Advisor returns as of September 30, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie AbbVie (NYSE: ABBV) isn't just an ordinary dividend stock; it's a member of dividend royalty. AbbVie has raised its dividend payo... | AbbVie AbbVie (NYSE: ABBV) isn't just an ordinary dividend stock; it's a member of dividend royalty. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie has raised its dividend payo... | AbbVie AbbVie (NYSE: ABBV) isn't just an ordinary dividend stock; it's a member of dividend royalty. AbbVie has raised its dividend payout by more than 250% since spinning off from Abbott Labs in 2013. But AbbVie loses U.S. exclusivity for Humira next year. |
23,055 | 2022-10-25 00:00:00 UTC | 3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink | ABBV | https://www.nasdaq.com/articles/3-hail-mary-plays-to-bring-your-stock-portfolio-back-from-the-brink-1 | null | null | Has your portfolio's value taken an unusually big hit this year? Perhaps you've suffered what most investors would consider a complete wipeout. Maybe you're rethinking when -- or even if -- you'll be able to retire.
Not to suggest that the emotional devastation isn't just as difficult as the financial loss, but these t... | AbbVie, Johnson & Johnson subsidiary Jansenn Biotech, BioNTech, and Novartis are just some of the pharma companies using Genmab's proprietary know-how to develop therapies. It's a hint that people still believe the stock's current reduced price fairly reflects the company's plausible future despite the black eye stemmi... | AbbVie, Johnson & Johnson subsidiary Jansenn Biotech, BioNTech, and Novartis are just some of the pharma companies using Genmab's proprietary know-how to develop therapies. Its flagship Singularity XDR (extended detection response) platform does it all, and does so largely on its own. Genmab Finally, add Danish biophar... | AbbVie, Johnson & Johnson subsidiary Jansenn Biotech, BioNTech, and Novartis are just some of the pharma companies using Genmab's proprietary know-how to develop therapies. Analysts are modeling 2023 revenue growth of 64%, which should reduce this year's likely loss of $0.81 per share to a loss of only $0.47 next year.... | AbbVie, Johnson & Johnson subsidiary Jansenn Biotech, BioNTech, and Novartis are just some of the pharma companies using Genmab's proprietary know-how to develop therapies. Analysts are modeling 2023 revenue growth of 64%, which should reduce this year's likely loss of $0.81 per share to a loss of only $0.47 next year.... |
23,056 | 2022-10-24 00:00:00 UTC | Noteworthy Monday Option Activity: ABBV, ADBE, XOM | ABBV | https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-abbv-adbe-xom | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 26,896 contracts have traded so far, representing approximately 2.7 million underlying shares. That amounts to about 48.6% of ABBV's average daily trading volume over the p... | Especially high volume was seen for the $150 strike call option expiring November 18, 2022, with 3,101 contracts trading so far today, representing approximately 310,100 underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol:... | Especially high volume was seen for the $150 strike call option expiring November 18, 2022, with 3,101 contracts trading so far today, representing approximately 310,100 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $150 strike highlighted in orange: Adobe In... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 26,896 contracts have traded so far, representing approximately 2.7 million underlying shares. Especially high volume was seen for the $150 strike call option expiring Nove... | Below is a chart showing XOM's trailing twelve month trading history, with the $100 strike highlighted in orange: For the various different available expirations for ABBV options, ADBE options, or XOM options, visit StockOptionsChannel.com. Among the underlying components of the S&P 500 index, we saw noteworthy options... |
23,057 | 2022-10-24 00:00:00 UTC | The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-jj-roche-eli-lilly-and-abbvie | null | null | For Immediate Release
Chicago, IL – October 24, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: J&J JNJ, Roche's RHHBY, El... | Stocks recently featured in the blog include: J&J JNJ, Roche's RHHBY, Eli Lilly LLY and AbbVie ABBV. The deal will provide AbbVie access to DJS' proprietary HEPTAD platform, which, coupled with its capabilities in biotherapeutics research, can be used to make antibody therapeutics against difficult-to-drug protein targ... | Stocks recently featured in the blog include: J&J JNJ, Roche's RHHBY, Eli Lilly LLY and AbbVie ABBV. AbbVie's New Antibody Deal: AbbVie announced the acquisition of private biotech, DJS Antibodies that makes antibody medicines targeting difficult-to-drug protein targets. Eli Lilly andAbbVie announced small acquisitions... | Stocks recently featured in the blog include: J&J JNJ, Roche's RHHBY, Eli Lilly LLY and AbbVie ABBV. Eli Lilly andAbbVie announced small acquisitions. AbbVie's New Antibody Deal: AbbVie announced the acquisition of private biotech, DJS Antibodies that makes antibody medicines targeting difficult-to-drug protein targets... | Stocks recently featured in the blog include: J&J JNJ, Roche's RHHBY, Eli Lilly LLY and AbbVie ABBV. Eli Lilly andAbbVie announced small acquisitions. AbbVie's New Antibody Deal: AbbVie announced the acquisition of private biotech, DJS Antibodies that makes antibody medicines targeting difficult-to-drug protein targets... |
23,058 | 2022-10-24 00:00:00 UTC | AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-to-report-q3-earnings%3A-whats-in-the-cards | null | null | AbbVie ABBV will report third-quarter 2022 results on Oct 28, before market open. In the last reported quarter, the company delivered an earnings surprise of 1.81%.
AbbVie’s stock has increased 8.6% so far this year against the industry’s 1.5% decline.
Image Source: Zacks Investment Research
This large drugmaker’s per... | On theearnings call investors’ focus will likely be on AbbVie’s strategies around Humira following its potential loss of exclusivity in the United States, which is expected next year. AbbVie ABBV will report third-quarter 2022 results on Oct 28, before market open. AbbVie’s stock has increased 8.6% so far this year aga... | AbbVie markets Imbruvica in partnership with Johnson & Johnson JNJ and Venclexta in partnership with Roche RHHBY. AbbVie ABBV will report third-quarter 2022 results on Oct 28, before market open. AbbVie’s stock has increased 8.6% so far this year against the industry’s 1.5% decline. | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Factors to Consider Strong demand for immunology and aesthetic products is expected to drive AbbVie’s third-quarter 2022 sales. AbbVie ABBV will report third-quarter 2022 results on Oct 28, before market open. AbbVie’s stock has incre... | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Factors to Consider Strong demand for immunology and aesthetic products is expected to drive AbbVie’s third-quarter 2022 sales. AbbVie ABBV will report third-quarter 2022 results on Oct 28, before market open. AbbVie’s stock has incre... |
23,059 | 2022-10-22 00:00:00 UTC | 3 Healthcare Stocks That Are Too Cheap to Ignore | ABBV | https://www.nasdaq.com/articles/3-healthcare-stocks-that-are-too-cheap-to-ignore-2 | null | null | This is a great time to hunt for deals in the equity markets. Many quality stocks continue to fall, carried downward in part by the momentum of the broader market, and even among those that are somewhat defying the trend, some now trade at more reasonable valuations than they have in quite a while.
The healthcare secto... | And in my view, AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) all look like bargains now. ABBV data by YCharts The case for AbbVie AbbVie's shares are up 5% since January, despite the fact that Humira, its best-selling drug, will face biosimilar competition in the U.S. starting next year. AbbVie h... | And in my view, AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) all look like bargains now. ABBV data by YCharts The case for AbbVie AbbVie's shares are up 5% since January, despite the fact that Humira, its best-selling drug, will face biosimilar competition in the U.S. starting next year. AbbVie h... | For investors, it's also worth noting that AbbVie this year joined the ranks of the Dividend Kings when management raised its payout for the 50th consecutive year (including the period before it was spun off from Abbott Labs). And in my view, AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) all look ... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! And in my view, AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) all look like bargains now. ABBV data by YCharts The case for AbbVie AbbVie's shares are up 5% since January... |
23,060 | 2022-10-21 00:00:00 UTC | FDA Approves AbbVie's Rinvoq For Treatment Of Active Non-radiographic Axial Spondyloarthritis | ABBV | https://www.nasdaq.com/articles/fda-approves-abbvies-rinvoq-for-treatment-of-active-non-radiographic-axial | null | null | (RTTNews) - AbbVie (ABBV) Friday announces that the U.S. Food and Drug Administration (FDA) has approved Rinvoq, an oral therapy for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis fact... | (RTTNews) - AbbVie (ABBV) Friday announces that the U.S. Food and Drug Administration (FDA) has approved Rinvoq, an oral therapy for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis fact... | (RTTNews) - AbbVie (ABBV) Friday announces that the U.S. Food and Drug Administration (FDA) has approved Rinvoq, an oral therapy for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis fact... | (RTTNews) - AbbVie (ABBV) Friday announces that the U.S. Food and Drug Administration (FDA) has approved Rinvoq, an oral therapy for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis fact... | (RTTNews) - AbbVie (ABBV) Friday announces that the U.S. Food and Drug Administration (FDA) has approved Rinvoq, an oral therapy for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis fact... |
23,061 | 2022-10-21 00:00:00 UTC | AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-reports-next-week%3A-wall-street-expects-earnings-growth-1 | null | null | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2022. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock ... | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2022. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have r... | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2022. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have r... | For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended... | For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended... |
23,062 | 2022-10-21 00:00:00 UTC | AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-to-boost-immunology-pipeline-with-new-acquisition | null | null | AbbVie Inc. ABBV recently announced that it has acquired UK-based private biotech, DJS Antibodies Ltd, to develop novel antibodies against difficult-to-drug protein targets in immunology.
DJS utilizes its proprietary HEPTAD platform for antibody discovery with specific capabilities targeting transmembrane protein targe... | With the acquisition of DJS, ABBV will be able to access this unique platform, which, coupled with its own capabilities in biotherapeutics research, can be used to make antibody therapeutics against difficult-to-drug protein targets. Image Source: Zacks Investment Research AbbVie is presently focused on strengthening i... | AbbVie Inc. ABBV recently announced that it has acquired UK-based private biotech, DJS Antibodies Ltd, to develop novel antibodies against difficult-to-drug protein targets in immunology. With the acquisition of DJS, ABBV will be able to access this unique platform, which, coupled with its own capabilities in biotherap... | Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie Inc. ABBV recently announced that it has acquired UK-based private biotech, DJS Antibodies Ltd, to develop novel antibodies against difficult-to-drug protein targets in immunology. With the acquisition of DJS, ABBV will be able to a... | AbbVie Inc. ABBV recently announced that it has acquired UK-based private biotech, DJS Antibodies Ltd, to develop novel antibodies against difficult-to-drug protein targets in immunology. With the acquisition of DJS, ABBV will be able to access this unique platform, which, coupled with its own capabilities in biotherap... |
23,063 | 2022-10-21 00:00:00 UTC | Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-jnj-q3-earnings-beat-rhhby-sales-weak-lly-abbv-ink-ma-deals | null | null | This week, J&J JNJ began the third-quarter earnings season for the drug and biotech sector with an earnings and sales beat. Weak sales of COVID-related medicines and tests hurt Roche’s RHHBY third-quarter sales. Eli Lilly LLY and AbbVie ABBV announced small acquisitions.
Recap of the Week’s Most Important Stories
J&J B... | The deal will provide AbbVie access to DJS’ proprietary HEPTAD platform, which, coupled with its capabilities in biotherapeutics research, can be used to make antibody therapeutics against difficult-to-drug protein targets in immunology. Eli Lilly LLY and AbbVie ABBV announced small acquisitions. AbbVie’s New Antibody ... | AbbVie’s New Antibody Deal: AbbVie announced the acquisition of private biotech, DJS Antibodies that makes antibody medicines targeting difficult-to-drug protein targets. Eli Lilly LLY and AbbVie ABBV announced small acquisitions. The deal will provide AbbVie access to DJS’ proprietary HEPTAD platform, which, coupled w... | Eli Lilly LLY and AbbVie ABBV announced small acquisitions. AbbVie’s New Antibody Deal: AbbVie announced the acquisition of private biotech, DJS Antibodies that makes antibody medicines targeting difficult-to-drug protein targets. The deal will provide AbbVie access to DJS’ proprietary HEPTAD platform, which, coupled w... | Eli Lilly LLY and AbbVie ABBV announced small acquisitions. AbbVie’s New Antibody Deal: AbbVie announced the acquisition of private biotech, DJS Antibodies that makes antibody medicines targeting difficult-to-drug protein targets. The deal will provide AbbVie access to DJS’ proprietary HEPTAD platform, which, coupled w... |
23,064 | 2022-10-21 00:00:00 UTC | 3 Dividend Aristocrats to Buy Right Now With No Hesitation | ABBV | https://www.nasdaq.com/articles/3-dividend-aristocrats-to-buy-right-now-with-no-hesitation | null | null | It can sometimes be difficult to make a decision about buying a stock. That's especially the case when the overall market is highly volatile.
But investing in high-quality stocks can help make the process less painful. Most companies that belong to the elite group of Dividend Aristocrats -- S&P 500 members that have in... | Despite the market-beating returns, AbbVie's valuation remains attractive, with shares trading at a little over 12 times expected earnings. You might be surprised by AbbVie's rise considering that the company faces the loss of U.S. exclusivity for its top-selling drug, Humira, in just a few months. AbbVie AbbVie (NYSE:... | Unlike AbbVie, Air Products hasn't delivered positive returns so far in 2022. AbbVie AbbVie (NYSE: ABBV) has increased its dividend for 50 years in a row. Despite the market-beating returns, AbbVie's valuation remains attractive, with shares trading at a little over 12 times expected earnings. | AbbVie AbbVie (NYSE: ABBV) has increased its dividend for 50 years in a row. See the 10 stocks *Stock Advisor returns as of September 30, 2022 Keith Speights has positions in AbbVie and Air Products & Chemicals. Despite the market-beating returns, AbbVie's valuation remains attractive, with shares trading at a little o... | Unlike AbbVie, Air Products hasn't delivered positive returns so far in 2022. * They just revealed what they believe are the ten best stocks for investors to buy right now… and AbbVie wasn't one of them! AbbVie AbbVie (NYSE: ABBV) has increased its dividend for 50 years in a row. |
23,065 | 2022-10-20 00:00:00 UTC | AbbVie (ABBV) Stock Moves -0.14%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.14%3A-what-you-should-know | null | null | AbbVie (ABBV) closed at $142.93 in the latest trading session, marking a -0.14% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.8%. Elsewhere, the Dow lost 0.3%, while the tech-heavy Nasdaq lost 0.03%.
Prior to today's trading, shares of the drugmaker had gained 2.01% over the past ... | AbbVie (ABBV) closed at $142.93 in the latest trading session, marking a -0.14% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be October 28, 2022. Investors should also note any recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $142.93 in the latest trading session, marking a -0.14% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be October 28, 2022. Investors should also note any recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $142.93 in the latest trading session, marking a -0.14% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be October 28, 2022. Investors should also note any recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed at $142.93 in the latest trading session, marking a -0.14% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be October 28, 2022. Investors should also note any recent changes to analyst estimates for AbbVie. |
23,066 | 2022-10-20 00:00:00 UTC | Walmart to pay $215 mln to settle Florida opioid claims | ABBV | https://www.nasdaq.com/articles/walmart-to-pay-%24215-mln-to-settle-florida-opioid-claims-0 | null | null | By Brendan Pierson
Oct 20 (Reuters) - Walmart Inc WMT.N has agreed to pay $215 million to resolve claims its pharmacies fueled an epidemic of opioid addiction in Florida, the state's attorney general announced on Thursday.
As part of the deal, Walmart has also agreed to dispense 672,000 treatment kits with the anti-ove... | The settlement comes on top of previous deals the state struck with pharmacy operators Walgreens Boots Alliance WBA.Oand CVS Health CorpCVS.N, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TAand AbbVie Inc ABBV.N, and others. By Brendan Pierson Oct 20 (Reuters) - Walmart Inc WMT.N has agreed to pay $215 million to... | The settlement comes on top of previous deals the state struck with pharmacy operators Walgreens Boots Alliance WBA.Oand CVS Health CorpCVS.N, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TAand AbbVie Inc ABBV.N, and others. By Brendan Pierson Oct 20 (Reuters) - Walmart Inc WMT.N has agreed to pay $215 million to... | The settlement comes on top of previous deals the state struck with pharmacy operators Walgreens Boots Alliance WBA.Oand CVS Health CorpCVS.N, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TAand AbbVie Inc ABBV.N, and others. By Brendan Pierson Oct 20 (Reuters) - Walmart Inc WMT.N has agreed to pay $215 million to... | The settlement comes on top of previous deals the state struck with pharmacy operators Walgreens Boots Alliance WBA.Oand CVS Health CorpCVS.N, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TAand AbbVie Inc ABBV.N, and others. "I'm grateful for Walmart stepping up and agreeing to partner with the state to provide l... |
23,067 | 2022-10-20 00:00:00 UTC | AbbVie To Buy UK-based Biotechnology Company DJS Antibodies For About $255 Mln | ABBV | https://www.nasdaq.com/articles/abbvie-to-buy-uk-based-biotechnology-company-djs-antibodies-for-about-%24255-mln | null | null | (RTTNews) - AbbVie (ABBV) said that it has agreed to buy a privately-held UK-based biotechnology company DJS Antibodies Ltd for about $255 million in cash.
DJS shareholders remain eligible for potential additional payments upon the achievement of certain development milestones related to the success of the DJS-002 prog... | (RTTNews) - AbbVie (ABBV) said that it has agreed to buy a privately-held UK-based biotechnology company DJS Antibodies Ltd for about $255 million in cash. AbbVie anticipates retaining all current DJS employees and its facility in Oxford. DJS shareholders remain eligible for potential additional payments upon the achie... | (RTTNews) - AbbVie (ABBV) said that it has agreed to buy a privately-held UK-based biotechnology company DJS Antibodies Ltd for about $255 million in cash. AbbVie anticipates retaining all current DJS employees and its facility in Oxford. DJS is backed by founding investors Oxford Science Enterprises and Johnson & John... | (RTTNews) - AbbVie (ABBV) said that it has agreed to buy a privately-held UK-based biotechnology company DJS Antibodies Ltd for about $255 million in cash. AbbVie anticipates retaining all current DJS employees and its facility in Oxford. DJS Antibodies is a privately-held UK-based biotechnology company dedicated to di... | (RTTNews) - AbbVie (ABBV) said that it has agreed to buy a privately-held UK-based biotechnology company DJS Antibodies Ltd for about $255 million in cash. AbbVie anticipates retaining all current DJS employees and its facility in Oxford. DJS shareholders remain eligible for potential additional payments upon the achie... |
23,068 | 2022-10-20 00:00:00 UTC | AbbVie: SKYRIZI Gets Health Canada Approval To Treat Moderately To Severely Active Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbvie%3A-skyrizi-gets-health-canada-approval-to-treat-moderately-to-severely-active-crohns | null | null | (RTTNews) - AbbVie (ABBV) announced Health Canada approval for SKYRIZI for the treatment of adults with moderately to severely active Crohn's disease. The company said the third approved indication for SKYRIZI is supported by data from three phase 3 clinical trials ? ADVANCE, MOTIVATE and FORTIFY.
Tracey Ramsay, Vice P... | (RTTNews) - AbbVie (ABBV) announced Health Canada approval for SKYRIZI for the treatment of adults with moderately to severely active Crohn's disease. Tracey Ramsay, Vice President and General Manager, AbbVie Canada, said: "This approval represents the first new treatment option in six years for people with moderately ... | (RTTNews) - AbbVie (ABBV) announced Health Canada approval for SKYRIZI for the treatment of adults with moderately to severely active Crohn's disease. Tracey Ramsay, Vice President and General Manager, AbbVie Canada, said: "This approval represents the first new treatment option in six years for people with moderately ... | (RTTNews) - AbbVie (ABBV) announced Health Canada approval for SKYRIZI for the treatment of adults with moderately to severely active Crohn's disease. Tracey Ramsay, Vice President and General Manager, AbbVie Canada, said: "This approval represents the first new treatment option in six years for people with moderately ... | (RTTNews) - AbbVie (ABBV) announced Health Canada approval for SKYRIZI for the treatment of adults with moderately to severely active Crohn's disease. Tracey Ramsay, Vice President and General Manager, AbbVie Canada, said: "This approval represents the first new treatment option in six years for people with moderately ... |
23,069 | 2022-10-19 00:00:00 UTC | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | https://www.nasdaq.com/articles/investors-heavily-search-abbvie-inc.-abbv%3A-here-is-what-you-need-to-know-1 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned +2%, compared to the Zacks S&P 500 composite's -3.8%... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals indus... | Last Reported Results and Surprise History AbbVie reported revenues of $14.58 billion in the last reported quarter, representing a year-over-year change of +4.5%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbV... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which Abb... | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 1.3%. For the current quarter, AbbVie is expected to post earnings of $3.56 per share, indicating a change of +6.9% from the year-ago quart... |
23,070 | 2022-10-18 00:00:00 UTC | VTV, KO, PEP, ABBV: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/vtv-ko-pep-abbv%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $859.4 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 724,762,192 to 731,450... | Among the largest underlying components of VTV, in trading today Coca-Cola Co (Symbol: KO) is up about 1.4%, PepsiCo Inc (Symbol: PEP) is up about 1.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performan... | Among the largest underlying components of VTV, in trading today Coca-Cola Co (Symbol: KO) is up about 1.4%, PepsiCo Inc (Symbol: PEP) is up about 1.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.1%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performan... | Among the largest underlying components of VTV, in trading today Coca-Cola Co (Symbol: KO) is up about 1.4%, PepsiCo Inc (Symbol: PEP) is up about 1.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one... | Among the largest underlying components of VTV, in trading today Coca-Cola Co (Symbol: KO) is up about 1.4%, PepsiCo Inc (Symbol: PEP) is up about 1.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one... |
23,071 | 2022-10-18 00:00:00 UTC | Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't? | ABBV | https://www.nasdaq.com/articles/do-options-traders-know-something-about-abbvie-abbv-stock-we-dont-0 | null | null | Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 20, 2023 $47.50 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is ex... | Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for AbbVie shares, but what is the fundamental picture for the company? Currently, AbbVie is a Zacks Rank #3 (Hold) in the Large Cap Pharmaceuticals indu... | Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for AbbVie shares, but what is the fundamental picture for the company? Currently, AbbVie is a Zacks Rank #3 (Hold) in the Large Cap Pharmaceuticals indu... | Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for AbbVie shares, but what is the fundamental picture for the company? Currently, AbbVie is a Zacks Rank #3 (Hold) in the Large Cap Pharmaceuticals indu... | Given the way analysts feel about AbbVie right now, this huge implied volatility could mean there’s a trade developing. Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for AbbVie shares, but what is th... |
23,072 | 2022-10-17 00:00:00 UTC | 4 Stocks I Own and Will Buy More of if the Market Crashes | ABBV | https://www.nasdaq.com/articles/4-stocks-i-own-and-will-buy-more-of-if-the-market-crashes | null | null | We all know that, on a basic level, profiting off the market means buying low and selling high. Yet it's challenging to confidently know when is the best time to pull the trigger. The market moves fast. The latest example of this was last Thursday when the Dow Jones Industrial Average went on a breakneck 1,500-point ro... | The four stocks are AbbVie (NYSE: ABBV), Amazon (NASDAQ: AMZN), Texas Instruments (NASDAQ: TXN), and Intuitive Surgical (NASDAQ: ISRG). AbbVie is a massive outperformer Boring old pharmaceutical giant AbbVie is the largest holding in my portfolio. That perception that what Abbvie offers is a necessity is one reason it ... | The four stocks are AbbVie (NYSE: ABBV), Amazon (NASDAQ: AMZN), Texas Instruments (NASDAQ: TXN), and Intuitive Surgical (NASDAQ: ISRG). AbbVie is a massive outperformer Boring old pharmaceutical giant AbbVie is the largest holding in my portfolio. That perception that what Abbvie offers is a necessity is one reason it ... | The four stocks are AbbVie (NYSE: ABBV), Amazon (NASDAQ: AMZN), Texas Instruments (NASDAQ: TXN), and Intuitive Surgical (NASDAQ: ISRG). AbbVie is a massive outperformer Boring old pharmaceutical giant AbbVie is the largest holding in my portfolio. That perception that what Abbvie offers is a necessity is one reason it ... | The four stocks are AbbVie (NYSE: ABBV), Amazon (NASDAQ: AMZN), Texas Instruments (NASDAQ: TXN), and Intuitive Surgical (NASDAQ: ISRG). AbbVie is a massive outperformer Boring old pharmaceutical giant AbbVie is the largest holding in my portfolio. That perception that what Abbvie offers is a necessity is one reason it ... |
23,073 | 2022-10-17 00:00:00 UTC | AbbVie Inc. (NYSE:ABBV) insiders sold US$8.4m worth of stock, a possible red flag that's yet to materialize | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-nyse%3Aabbv-insiders-sold-us%248.4m-worth-of-stock-a-possible-red-flag-thats-yet | null | null | While AbbVie Inc. (NYSE:ABBV) shareholders have enjoyed a good week with stock up 3.0%, they need remain vigilant. In spite of the relatively cheap prices, insiders made the decision to sell US$8.4m worth of stock in the last 12 months. This could be a warning indicator of vulnerabilities in the future.
While we would ... | While AbbVie Inc. (NYSE:ABBV) shareholders have enjoyed a good week with stock up 3.0%, they need remain vigilant. The Last 12 Months Of Insider Transactions At AbbVie The Independent Director, Roxanne Austin, made the biggest insider sale in the last 12 months. NYSE:ABBV Insider Trading Volume October 17th 2022 I will... | The Last 12 Months Of Insider Transactions At AbbVie The Independent Director, Roxanne Austin, made the biggest insider sale in the last 12 months. While AbbVie Inc. (NYSE:ABBV) shareholders have enjoyed a good week with stock up 3.0%, they need remain vigilant. NYSE:ABBV Insider Trading Volume October 17th 2022 I will... | The Last 12 Months Of Insider Transactions At AbbVie The Independent Director, Roxanne Austin, made the biggest insider sale in the last 12 months. While AbbVie Inc. (NYSE:ABBV) shareholders have enjoyed a good week with stock up 3.0%, they need remain vigilant. NYSE:ABBV Insider Trading Volume October 17th 2022 I will... | So What Do The AbbVie Insider Transactions Indicate? But note: AbbVie may not be the best stock to buy. While AbbVie Inc. (NYSE:ABBV) shareholders have enjoyed a good week with stock up 3.0%, they need remain vigilant. |
23,074 | 2022-10-17 00:00:00 UTC | 3 Dividend Stocks to Buy Now for a Lifetime of Passive Income | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-now-for-a-lifetime-of-passive-income | null | null | It's a bloodbath out there. The S&P 500 fell another 1.6% last week. Now, the benchmark index consisting of the largest publicly traded stocks traded on U.S. markets is down a stunning 24.8% since the end of 2021.
With stock prices tanking left and right, investors looking for stocks to buy are increasingly interested ... | AbbVie Up until 2013, AbbVie (NYSE: ABBV) was Abbott Laboratories' biopharmaceutical segment. Right now you can get an above-average 3.9% yield from AbbVie shares because investors are worried about competition hammering U.S. Humira revenue next year. AbbVie launched Rinvoq for arthritis and Skyrizi for Psoriasis in 20... | AbbVie Up until 2013, AbbVie (NYSE: ABBV) was Abbott Laboratories' biopharmaceutical segment. Right now you can get an above-average 3.9% yield from AbbVie shares because investors are worried about competition hammering U.S. Humira revenue next year. AbbVie launched Rinvoq for arthritis and Skyrizi for Psoriasis in 20... | AbbVie Up until 2013, AbbVie (NYSE: ABBV) was Abbott Laboratories' biopharmaceutical segment. Right now you can get an above-average 3.9% yield from AbbVie shares because investors are worried about competition hammering U.S. Humira revenue next year. AbbVie launched Rinvoq for arthritis and Skyrizi for Psoriasis in 20... | AbbVie Up until 2013, AbbVie (NYSE: ABBV) was Abbott Laboratories' biopharmaceutical segment. Right now you can get an above-average 3.9% yield from AbbVie shares because investors are worried about competition hammering U.S. Humira revenue next year. AbbVie launched Rinvoq for arthritis and Skyrizi for Psoriasis in 20... |
23,075 | 2022-10-16 00:00:00 UTC | 3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off | ABBV | https://www.nasdaq.com/articles/3-supercharged-dividend-stocks-to-buy-if-theres-a-stock-market-sell-off-2 | null | null | Medical stocks don't generally have high dividends, but Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), and Gilead Sciences (NASDAQ: GILD) all have dividends with yields of 3.5% or more, and these pharmaceuticals stocks serve as a great hedge against inflation because their business models are largely resistant to recessions.... | Medical stocks don't generally have high dividends, but Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), and Gilead Sciences (NASDAQ: GILD) all have dividends with yields of 3.5% or more, and these pharmaceuticals stocks serve as a great hedge against inflation because their business models are largely resistant to recessions.... | Medical stocks don't generally have high dividends, but Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), and Gilead Sciences (NASDAQ: GILD) all have dividends with yields of 3.5% or more, and these pharmaceuticals stocks serve as a great hedge against inflation because their business models are largely resistant to recessions.... | Medical stocks don't generally have high dividends, but Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), and Gilead Sciences (NASDAQ: GILD) all have dividends with yields of 3.5% or more, and these pharmaceuticals stocks serve as a great hedge against inflation because their business models are largely resistant to recessions.... | Medical stocks don't generally have high dividends, but Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), and Gilead Sciences (NASDAQ: GILD) all have dividends with yields of 3.5% or more, and these pharmaceuticals stocks serve as a great hedge against inflation because their business models are largely resistant to recessions.... |
23,076 | 2022-10-14 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-4 | null | null | AbbVie (ABBV) closed the most recent trading day at $142.94, moving +0.01% from the previous trading session. The stock outpaced the S&P 500's daily loss of 2.37%. At the same time, the Dow lost 1.35%, and the tech-heavy Nasdaq lost 0.21%.
Prior to today's trading, shares of the drugmaker had gained 0.29% over the past... | AbbVie (ABBV) closed the most recent trading day at $142.94, moving +0.01% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.57 per share. | AbbVie (ABBV) closed the most recent trading day at $142.94, moving +0.01% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.57 per share. | AbbVie (ABBV) closed the most recent trading day at $142.94, moving +0.01% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.57 per share. | In that report, analysts expect AbbVie to post earnings of $3.57 per share. AbbVie (ABBV) closed the most recent trading day at $142.94, moving +0.01% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. |
23,077 | 2022-10-13 00:00:00 UTC | 3 Dividend Stocks That Could Pay You for the Rest of Your Life | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-could-pay-you-for-the-rest-of-your-life | null | null | Amid economic and geopolitical uncertainty, financial markets have floundered. The S&P 500 index has tumbled about 25% so far in 2022. Yet some high-quality components of the index have not been hurt in one way that is very important to income investors: dividends.
Despite the tough economic environment, Hormel Foods (... | Despite the tough economic environment, Hormel Foods (NYSE: HRL), AbbVie (NYSE: ABBV), and Aflac (NYSE: AFL) each raised their payouts to shareholders over the last 12 months. AbbVie Including its time as the pharmaceutical division of Abbott Laboratories until its spin-off was completed in 2013, AbbVie is a Dividend K... | Despite the tough economic environment, Hormel Foods (NYSE: HRL), AbbVie (NYSE: ABBV), and Aflac (NYSE: AFL) each raised their payouts to shareholders over the last 12 months. AbbVie Including its time as the pharmaceutical division of Abbott Laboratories until its spin-off was completed in 2013, AbbVie is a Dividend K... | AbbVie Including its time as the pharmaceutical division of Abbott Laboratories until its spin-off was completed in 2013, AbbVie is a Dividend King with 50 straight years of dividend growth. Despite the tough economic environment, Hormel Foods (NYSE: HRL), AbbVie (NYSE: ABBV), and Aflac (NYSE: AFL) each raised their pa... | Despite the tough economic environment, Hormel Foods (NYSE: HRL), AbbVie (NYSE: ABBV), and Aflac (NYSE: AFL) each raised their payouts to shareholders over the last 12 months. AbbVie Including its time as the pharmaceutical division of Abbott Laboratories until its spin-off was completed in 2013, AbbVie is a Dividend K... |
23,078 | 2022-10-11 00:00:00 UTC | Merck Stock Is Likely A Better Pick Over Its Peer | ABBV | https://www.nasdaq.com/articles/merck-stock-is-likely-a-better-pick-over-its-peer | null | null | We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 3.9x trailing revenues vs. 10.8x for Eli Lilly. Investors have assigned a higher P/S multiple for LLY stock owing to its pipeline potential. If we look at stock retur... | We compare a slew of factors, such as historical revenue growth, returns, and valuation multiple, in an interactive dashboard analysis of Merck vs. Eli Lilly: Which Stock Is A Better Bet? Eli Lilly’s revenue growth has been driven by continued market share gains for drugs such as Trulicity, Verzenio, Jardiance, and its... | We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 3.9x trailing revenues vs. 10.8x for Eli Lilly. However, if we look at a longer time frame, Merck’s sales grew at an average growth rate of 5.3% to $48.7 billion in 20... | We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 3.9x trailing revenues vs. 10.8x for Eli Lilly. If we look at stock returns, Eli Lilly’s 18% growth this year is slightly better than the 14% return for Merck stock, b... | We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 3.9x trailing revenues vs. 10.8x for Eli Lilly. There is more to the comparison, and in the sections below, we discuss why we believe MRK stock will offer better retur... |
23,079 | 2022-10-11 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, Abbott Laboratories and American Express | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-abbott-laboratories-and-american-express | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 10/13/22, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.41 on 11/15/22, Abbott La... | As a percentage of ABBV's recent stock price of $138.94, this dividend works out to approximately 1.01%, so look for shares of AbbVie Inc to trade 1.01% lower — all else being equal — when ABBV shares open for trading on 10/13/22. If they do continue, the current estimated yields on annualized basis would be 4.06% for ... | Looking at the universe of stocks we cover at Dividend Channel, on 10/13/22, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.41 on 11/15/22, Abbott La... | Looking at the universe of stocks we cover at Dividend Channel, on 10/13/22, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.41 on 11/15/22, Abbott La... | As a percentage of ABBV's recent stock price of $138.94, this dividend works out to approximately 1.01%, so look for shares of AbbVie Inc to trade 1.01% lower — all else being equal — when ABBV shares open for trading on 10/13/22. If they do continue, the current estimated yields on annualized basis would be 4.06% for ... |
23,080 | 2022-10-11 00:00:00 UTC | 2 Top Stocks to Buy in October and Hold Forever | ABBV | https://www.nasdaq.com/articles/2-top-stocks-to-buy-in-october-and-hold-forever | null | null | If you're looking for the best stocks to buy this month that you can hold in your portfolio -- and add to again and again -- you've come to the right place. While the stock market may be facing a turbulent environment at the moment, it's always a good time to invest in wonderful companies with great businesses that can... | Beyond the diverse streams of growth that AbbVie can tap into from its current portfolio, it also boasts an impressive pipeline of candidates that target diseases from rheumatoid arthritis to Alzheimer's to small cell lung cancer. AbbVie: A no-brainer for income investors If you're not familiar with pharmaceutical gian... | AbbVie: A no-brainer for income investors If you're not familiar with pharmaceutical giant AbbVie (NYSE: ABBV), you're likely familiar with one of its star products, Humira. Now, with patent exclusivity on the drug set to expire in the U.S. in 2023, you'll be glad to learn that Abbvie also has other highly lucrative pr... | See the 10 stocks *Stock Advisor returns as of September 30, 2022 Rachel Warren has positions in AbbVie and DexCom. AbbVie: A no-brainer for income investors If you're not familiar with pharmaceutical giant AbbVie (NYSE: ABBV), you're likely familiar with one of its star products, Humira. Now, with patent exclusivity o... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie: A no-brainer for income investors If you're not familiar with pharmaceutical giant AbbVie (NYSE: ABBV), you're likely familiar with one of its star products, Humira. Now, with patent e... |
23,081 | 2022-10-11 00:00:00 UTC | Better Bear-Market Buy: Abbott Laboratories vs. AbbVie Stock | ABBV | https://www.nasdaq.com/articles/better-bear-market-buy%3A-abbott-laboratories-vs.-abbvie-stock | null | null | It's inevitable that offspring are compared with their parents. This happens with famous people and not-so-famous people alike. And it also happens with companies. For example, Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV) in 2013. The two companies have been compared ever since.
There are pretty good ar... | However, AbbVie should quickly rebound after an initial sales decline thanks to other growth drivers in its lineup. Market researcher EvaluatePharma projects that AbbVie will become the biggest pharmaceutical company based on prescription-drug sales by 2028. This bright outlook combined with its other advantages make A... | This bright outlook combined with its other advantages make AbbVie a solid bear-market pick right now. For example, Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV) in 2013. Here are the cases for Abbott and AbbVie. | AbbVie: Checking off multiple boxes Keith Speights (AbbVie): I think that there are several reasons why AbbVie is a great stock to buy in the current bear market. For example, Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV) in 2013. Here are the cases for Abbott and AbbVie. | For example, Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV) in 2013. Here are the cases for Abbott and AbbVie. AbbVie: Checking off multiple boxes Keith Speights (AbbVie): I think that there are several reasons why AbbVie is a great stock to buy in the current bear market. |
23,082 | 2022-10-10 00:00:00 UTC | How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks | ABBV | https://www.nasdaq.com/articles/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks-17 | null | null | Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself.
And unfortunately, even retirees who have built a nest egg have good reason to be concerned - with the traditional approaches to retirement planning, income may no longer cover expenses. That means retirees ar... | AbbVie (ABBV) is currently shelling out a dividend of $1.41 per share, with a dividend yield of 4.06%. Check AbbVie (ABBV) dividend history here>>> American Tower (AMT) is paying out a dividend of $1.47 per share at the moment, with a dividend yield of 3.02% compared to the REIT and Equity Trust - Other industry's yiel... | Check AbbVie (ABBV) dividend history here>>> American Tower (AMT) is paying out a dividend of $1.47 per share at the moment, with a dividend yield of 3.02% compared to the REIT and Equity Trust - Other industry's yield of 4.64% and the S&P 500's yield. AbbVie (ABBV) is currently shelling out a dividend of $1.41 per sha... | Check AbbVie (ABBV) dividend history here>>> American Tower (AMT) is paying out a dividend of $1.47 per share at the moment, with a dividend yield of 3.02% compared to the REIT and Equity Trust - Other industry's yield of 4.64% and the S&P 500's yield. AbbVie (ABBV) is currently shelling out a dividend of $1.41 per sha... | AbbVie (ABBV) is currently shelling out a dividend of $1.41 per share, with a dividend yield of 4.06%. Check AbbVie (ABBV) dividend history here>>> American Tower (AMT) is paying out a dividend of $1.47 per share at the moment, with a dividend yield of 3.02% compared to the REIT and Equity Trust - Other industry's yiel... |
23,083 | 2022-10-10 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-49 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Get the latest Zacks research report on RLI — FREE Get the latest Zacks research report on ABBV — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Procter & Gamble Company (Symbol: PG) $124... | Procter & Gamble Company (Symbol: PG) $124.27 $159.36 28.24% California Water Service Group (Symbol: CWT) $53.24 $64.50 21.15% Walmart Inc (Symbol: WMT) $128.56 $152.46 18.59% RLI Corp (Symbol: RLI) $101.94 $120.00 17.72% AbbVie Inc (Symbol: ABBV) $138.76 $163.25 17.65% The average 12-month analyst targets are only tar... | Procter & Gamble Company (Symbol: PG) $124.27 $159.36 28.24% California Water Service Group (Symbol: CWT) $53.24 $64.50 21.15% Walmart Inc (Symbol: WMT) $128.56 $152.46 18.59% RLI Corp (Symbol: RLI) $101.94 $120.00 17.72% AbbVie Inc (Symbol: ABBV) $138.76 $163.25 17.65% The average 12-month analyst targets are only tar... | Procter & Gamble Company (Symbol: PG) $124.27 $159.36 28.24% California Water Service Group (Symbol: CWT) $53.24 $64.50 21.15% Walmart Inc (Symbol: WMT) $128.56 $152.46 18.59% RLI Corp (Symbol: RLI) $101.94 $120.00 17.72% AbbVie Inc (Symbol: ABBV) $138.76 $163.25 17.65% The average 12-month analyst targets are only tar... |
23,084 | 2022-10-09 00:00:00 UTC | 2 Top Healthcare Stocks Defying the Bear Market | ABBV | https://www.nasdaq.com/articles/2-top-healthcare-stocks-defying-the-bear-market-0 | null | null | Everyone's looking for safe harbors to park their cash amid a downwardly mobile market and globally fulminating economic turmoil. To merely beat the bear market, a stock needs to do better than lose nearly 20% of its value so far in 2022. The good news is that there are plenty of portfolio-ready stocks that continue to... | AbbVie Unlike Veru, AbbVie (NYSE: ABBV) is a major pharmaceutical company rather than a scrappy biotech. Nonetheless, with its quarterly free cash flow (FCF) rising by 102% in the last five years, it's clear that AbbVie's investment potential is far more than a short-term bear-market play. AbbVie's key to success is it... | AbbVie Unlike Veru, AbbVie (NYSE: ABBV) is a major pharmaceutical company rather than a scrappy biotech. Nonetheless, with its quarterly free cash flow (FCF) rising by 102% in the last five years, it's clear that AbbVie's investment potential is far more than a short-term bear-market play. AbbVie's key to success is it... | AbbVie Unlike Veru, AbbVie (NYSE: ABBV) is a major pharmaceutical company rather than a scrappy biotech. Nonetheless, with its quarterly free cash flow (FCF) rising by 102% in the last five years, it's clear that AbbVie's investment potential is far more than a short-term bear-market play. AbbVie's key to success is it... | AbbVie Unlike Veru, AbbVie (NYSE: ABBV) is a major pharmaceutical company rather than a scrappy biotech. Nonetheless, with its quarterly free cash flow (FCF) rising by 102% in the last five years, it's clear that AbbVie's investment potential is far more than a short-term bear-market play. AbbVie's key to success is it... |
23,085 | 2022-10-08 00:00:00 UTC | 3 Great Dividend Stocks to Buy in October | ABBV | https://www.nasdaq.com/articles/3-great-dividend-stocks-to-buy-in-october | null | null | Dividends are important -- and not just for income investors. More than half of the S&P 500's total return over the past 30 years came from reinvesting dividends.
We asked three Motley Fool contributors to identify great dividend stocks to buy in October. Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NY... | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Merck & Co. (NYSE: MRK). A growth king Keith Speights (AbbVie): Probably the first thing investors look for with a dividend stock is its yield. AbbVie doesn't disappoint on this front with a juicy dividend yield of 4.2%. | A growth king Keith Speights (AbbVie): Probably the first thing investors look for with a dividend stock is its yield. Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Merck & Co. (NYSE: MRK). AbbVie doesn't disappoint on this front with a juicy dividend yield of 4.2%. | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Merck & Co. (NYSE: MRK). A growth king Keith Speights (AbbVie): Probably the first thing investors look for with a dividend stock is its yield. AbbVie doesn't disappoint on this front with a juicy dividend yield of 4.2%. | A growth king Keith Speights (AbbVie): Probably the first thing investors look for with a dividend stock is its yield. Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Merck & Co. (NYSE: MRK). AbbVie doesn't disappoint on this front with a juicy dividend yield of 4.2%. |
23,086 | 2022-10-07 00:00:00 UTC | XLV, ABBV, ELV, MDT: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/xlv-abbv-elv-mdt%3A-etf-outflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $757.9 million dollar outflow -- that's a 2.0% decrease week over week (from 301,820,000 to 295,77... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.4%, Elevance Health Inc (Symbol: ELV) is off about 1.2%, and Medtronic PLC (Symbol: MDT) is lower by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.4%, Elevance Health Inc (Symbol: ELV) is off about 1.2%, and Medtronic PLC (Symbol: MDT) is lower by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year pr... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.4%, Elevance Health Inc (Symbol: ELV) is off about 1.2%, and Medtronic PLC (Symbol: MDT) is lower by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.4%, Elevance Health Inc (Symbol: ELV) is off about 1.2%, and Medtronic PLC (Symbol: MDT) is lower by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year pr... |
23,087 | 2022-10-07 00:00:00 UTC | Want $1,000 in Passive Income? Don't Make These 3 Mistakes | ABBV | https://www.nasdaq.com/articles/want-%241000-in-passive-income-dont-make-these-3-mistakes | null | null | If you're looking to invest with the goal of making $1,000 in annual passive income, you'll need to play your cards carefully. It might seem like a great idea to slam down a lot of money buying shares of a single company with a high dividend yield, or perhaps a business that has a history of hiking its dividend, but it... | But as a pharmaceutical company, AbbVie is exposed to a significant amount of risk from changes in drug pricing legislation, and that could potentially ruin your dividend returns. Take a high-quality dividend stock like AbbVie (NYSE: ABBV), for example. There's no guarantee that any individual change to the relevant re... | Take a high-quality dividend stock like AbbVie (NYSE: ABBV), for example. But as a pharmaceutical company, AbbVie is exposed to a significant amount of risk from changes in drug pricing legislation, and that could potentially ruin your dividend returns. There's no guarantee that any individual change to the relevant re... | Take a high-quality dividend stock like AbbVie (NYSE: ABBV), for example. But as a pharmaceutical company, AbbVie is exposed to a significant amount of risk from changes in drug pricing legislation, and that could potentially ruin your dividend returns. There's no guarantee that any individual change to the relevant re... | Take a high-quality dividend stock like AbbVie (NYSE: ABBV), for example. But as a pharmaceutical company, AbbVie is exposed to a significant amount of risk from changes in drug pricing legislation, and that could potentially ruin your dividend returns. There's no guarantee that any individual change to the relevant re... |
23,088 | 2022-10-06 00:00:00 UTC | Why Warren Buffett Thinks It's a Mistake to Dump Your Stocks in a Bear Market | ABBV | https://www.nasdaq.com/articles/why-warren-buffett-thinks-its-a-mistake-to-dump-your-stocks-in-a-bear-market | null | null | The S&P 500 is down 24% this year, and the stock market hasn't been a great place to be holding your money of late. Investors have been dumping stocks left and right, with many quality companies seeing their valuations plummet as interest rate increases and rising inflation have made people second-guess their investmen... | One example of a company that could make for a great long-term investment is drugmaker AbbVie (NYSE: ABBV), which has solid financials and a path to more growth. AbbVie's acquisition of Botox-maker Allergan a few years ago has diversified its business; Botox cosmetic sales rose 19% in its most recent quarter (ended Jun... | One example of a company that could make for a great long-term investment is drugmaker AbbVie (NYSE: ABBV), which has solid financials and a path to more growth. AbbVie's acquisition of Botox-maker Allergan a few years ago has diversified its business; Botox cosmetic sales rose 19% in its most recent quarter (ended Jun... | Buying and holding could pay off, now more than ever AbbVie and Adobe are just two examples of promising growth stocks to own for the long haul, but there are many other options out there that investors can load up on today. One example of a company that could make for a great long-term investment is drugmaker AbbVie (... | One example of a company that could make for a great long-term investment is drugmaker AbbVie (NYSE: ABBV), which has solid financials and a path to more growth. AbbVie's acquisition of Botox-maker Allergan a few years ago has diversified its business; Botox cosmetic sales rose 19% in its most recent quarter (ended Jun... |
23,089 | 2022-10-05 00:00:00 UTC | ABBV December 16th Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-december-16th-options-begin-trading | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 72 days until expiration the newly trading contracts represent a possible opportunity for sellers of ... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Considering the fact that the $145.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $140.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $145.00 strike price has a current bid of $5.20. Below is a chart showing ABB... | Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Considering the fact that the $145.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... |
23,090 | 2022-10-05 00:00:00 UTC | 3 Dividend Stocks to Buy In October and Hold Forever | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-in-october-and-hold-forever | null | null | If you're like most investors, 2022 has been a difficult year that you would rather forget. A war in Europe and the subsequent energy crisis it's causing would be enough to tank global stock markets in any given year. On top of Russia's invasion of Ukraine, markets are also reeling from rapidly rising interest rates in... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company that has only been making and increasing its dividend since 2013. AbbVie split to shield Abbott from the imminent collapse of the company's best-selling drug, Humira. AbbVie looks like a buy now because, in years past, it expertly funneled Humira profits into th... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company that has only been making and increasing its dividend since 2013. AbbVie split to shield Abbott from the imminent collapse of the company's best-selling drug, Humira. AbbVie looks like a buy now because, in years past, it expertly funneled Humira profits into th... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company that has only been making and increasing its dividend since 2013. AbbVie split to shield Abbott from the imminent collapse of the company's best-selling drug, Humira. AbbVie looks like a buy now because, in years past, it expertly funneled Humira profits into th... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company that has only been making and increasing its dividend since 2013. AbbVie split to shield Abbott from the imminent collapse of the company's best-selling drug, Humira. AbbVie looks like a buy now because, in years past, it expertly funneled Humira profits into th... |
23,091 | 2022-10-04 00:00:00 UTC | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | ABBV | https://www.nasdaq.com/articles/here-is-what-to-know-beyond-why-abbvie-inc.-abbv-is-a-trending-stock-1 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned +1.5% over the past month versus the Zacks S&P 500 composite's -6.2% chan... | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 0.2% over this period. AbbVie is expected to post earnings of $3.59 per share for the current quarter, representing a year-over-year change of +7.8%. | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 0.2% over this period. AbbVie is expected to post earnings of $3.59 per share for the current quarter, representing a year-over-year change of +7.8%. | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has ... | For the next fiscal year, the consensus earnings estimate of $11.67 indicates a change of -16% from what AbbVie is expected to report a year ago. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (AB... |
23,092 | 2022-10-04 00:00:00 UTC | Reata Pharma (RETA) is Striving Hard Despite Pipeline Setbacks | ABBV | https://www.nasdaq.com/articles/reata-pharma-reta-is-striving-hard-despite-pipeline-setbacks | null | null | Reata Pharmaceuticals RETA is a clinical-stage biopharma company focused on developing small molecule therapies for life-threatening diseases with few treatment options. The company currently has no marketed drugs in its portfolio.
However, the company is developing two of its lead pipeline candidates, namely, omavelo... | Reata reacquired the ex-US rights to develop, manufacture and commercialize bardoxolone and worldwide rights for omaveloxolone and its proprietary Nrf2 product platform from AbbVie ABBV in 2019. Reata made a cash payment of $330 million to AbbVie as a consideration for the reacquisition of the rights, primarily for rig... | Reata reacquired the ex-US rights to develop, manufacture and commercialize bardoxolone and worldwide rights for omaveloxolone and its proprietary Nrf2 product platform from AbbVie ABBV in 2019. Reata made a cash payment of $330 million to AbbVie as a consideration for the reacquisition of the rights, primarily for rig... | Reata reacquired the ex-US rights to develop, manufacture and commercialize bardoxolone and worldwide rights for omaveloxolone and its proprietary Nrf2 product platform from AbbVie ABBV in 2019. Reata made a cash payment of $330 million to AbbVie as a consideration for the reacquisition of the rights, primarily for rig... | AbbVie Inc. (ABBV): Free Stock Analysis Report Reata reacquired the ex-US rights to develop, manufacture and commercialize bardoxolone and worldwide rights for omaveloxolone and its proprietary Nrf2 product platform from AbbVie ABBV in 2019. Reata made a cash payment of $330 million to AbbVie as a consideration for the... |
23,093 | 2022-10-03 00:00:00 UTC | Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales? | ABBV | https://www.nasdaq.com/articles/can-abbvies-abbv-new-drugs-make-up-for-lost-humira-sales | null | null | AbbVie ABBV is presently focused on strengthening its immunology portfolio. While its anti-inflammatory drug Humira continues to be a key revenue driver of the company’s sales, it is set to lose exclusivity in the United States next year.
AbbVie’s flagship product, Humira, is approved in the United States and Europe fo... | Apart from immunology franchise, AbbVie also enjoys leadership positions in other key therapeutic areas, including hematologic oncology, neuroscience, aesthetics and eye care. Both ABBV and J&J co-exclusively market the drug in the United States The U.S. sales of Imbruvica are being hurt by lower new patient starts in ... | AbbVie’s flagship product, Humira, is approved in the United States and Europe for several autoimmune diseases like rheumatoid arthritis (RA), active psoriatic arthritis, active ankylosing spondylitis and Crohn’s disease (CD). Amgen, Biogen, Boehringer Ingelheim, Pfizer, Sandoz and many other companies also received FD... | AbbVie’s flagship product, Humira, is approved in the United States and Europe for several autoimmune diseases like rheumatoid arthritis (RA), active psoriatic arthritis, active ankylosing spondylitis and Crohn’s disease (CD). Amgen, Biogen, Boehringer Ingelheim, Pfizer, Sandoz and many other companies also received FD... | AbbVie expects combined sales of Skyrizi and Rinvoq to be more than $15 billion by 2025. AbbVie ABBV is presently focused on strengthening its immunology portfolio. AbbVie’s flagship product, Humira, is approved in the United States and Europe for several autoimmune diseases like rheumatoid arthritis (RA), active psori... |
23,094 | 2022-10-03 00:00:00 UTC | Bear Market Bargains: 3 Dividend Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/bear-market-bargains%3A-3-dividend-stocks-to-buy-now | null | null | Bear markets offer great opportunities to make money. The problem for many investors is that they're afraid to dip their toes in the water with stocks that are sinking.
But what if you could find stocks that have actually performed well, offer exceptional dividends, and are attractively valued? The good news is that th... | AbbVie also has other solid growth drivers in its lineup, including blood cancer drug Venclexta and antipsychotic Vraylar. But BMS is beating AbbVie (and most other stocks) on another important front: Its share price has soared nearly 15% year to date while the major indexes plunged. AbbVie AbbVie (NYSE: ABBV) belongs ... | Like AbbVie and Bristol Myers Squibb, Chevron is a bear market bargain that could also continue beating the market. AbbVie AbbVie (NYSE: ABBV) belongs to the exclusive group of stocks known as Dividend Kings. Admittedly, AbbVie hasn't delivered massive gains for shareholders this year. | AbbVie AbbVie (NYSE: ABBV) belongs to the exclusive group of stocks known as Dividend Kings. Like AbbVie and Bristol Myers Squibb, Chevron is a bear market bargain that could also continue beating the market. See the 10 stocks *Stock Advisor returns as of August 17, 2022 Keith Speights has positions in AbbVie and Brist... | Like AbbVie and Bristol Myers Squibb, Chevron is a bear market bargain that could also continue beating the market. AbbVie AbbVie (NYSE: ABBV) belongs to the exclusive group of stocks known as Dividend Kings. Admittedly, AbbVie hasn't delivered massive gains for shareholders this year. |
23,095 | 2022-10-02 00:00:00 UTC | Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks | ABBV | https://www.nasdaq.com/articles/got-%242000-buy-these-2-bear-market-beating-growth-stocks | null | null | With the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. And one solid way to protect your portfolio from falling share prices in the bear market is to load up on stocks that aren't having any trouble outperforming it.
On that note, there... | If you invest $1,000 in AbbVie today and the average price target of $158.30 as estimated by financial analysts for a year from now turns out to be correct, you'll have around $1,107, which isn't half bad, especially if the market continues to fall. AbbVie AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bu... | Jazz Pharmaceuticals The recent history of Jazz Pharmaceuticals (NASDAQ: JAZZ) is similar to AbbVie's, and that's why its shares are up by 1.2% even while the market is contracting sharply. AbbVie AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green li... | Skyrizi brought in more than $1.2 billion for the company in the second quarter alone out of its total revenue of more than $14.5 billion, and the positive update is a piece of evidence which suggests that AbbVie will be making a lot more money from the drug in the future than it is today. Jazz Pharmaceuticals The rece... | Jazz Pharmaceuticals The recent history of Jazz Pharmaceuticals (NASDAQ: JAZZ) is similar to AbbVie's, and that's why its shares are up by 1.2% even while the market is contracting sharply. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Ab... |
23,096 | 2022-10-01 00:00:00 UTC | Here's Why This Dividend King Is a Buy | ABBV | https://www.nasdaq.com/articles/heres-why-this-dividend-king-is-a-buy | null | null | Mounting concerns over the state of the global economy have pushed stocks to their lowest levels of the year. Accordingly, the S&P 500 index has plunged 23% so far this year. But one sector of the market is holding its own in this downward cycle.
Many pharma stocks have squeezed out marginal gains in their share prices... | Thanks to the company's pipeline of nearly five dozen molecules currently in clinical development, AbbVie has plenty of potential new drugs to help it keep growing over the medium term. It should also give AbbVie some breathing room to maintain its dividend in 2023 when profits are likely to dip a bit over the aforemen... | This is how AbbVie's adjusted diluted EPS growth was significantly higher than its net revenue growth for the quarter. But because of how the spin-off was handled (with AbbVie maintaining a dividend), AbbVie was able to maintain its streak of consecutive annual dividend increases. Among the most notable stocks to do so... | AbbVie has a diverse and powerful portfolio of drugs AbbVie is best known as the maker of the top-selling drug in the world, Humira. AbbVie's market-beating dividend is safe AbbVie's strong performance allows the company to generate enough free cash flow to support a generous dividend which yields 3.9%, more than twice... | Besides Humira, AbbVie's portfolio includes 11 other drugs likely to generate at least $1 billion each in net revenue for 2022. Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie has a diverse and powerful portfolio of drugs AbbVie is best known as the maker of the... |
23,097 | 2022-09-30 00:00:00 UTC | ABBV Dividend Yield Pushes Past 4% | ABBV | https://www.nasdaq.com/articles/abbv-dividend-yield-pushes-past-4 | null | null | Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.64), with the stock changing hands as low as $134.31 on the day. Dividends are particularly important for investors ... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.64), with the stock changing hands as low as $134.31 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, gi... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.64), with the stock changing hands as low as $134.31 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, gi... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.64), with the stock changing hands as low as $134.31 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, gi... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.64), with the stock changing hands as low as $134.31 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, gi... |
23,098 | 2022-09-30 00:00:00 UTC | Notable Friday Option Activity: ABBV, FCX, UAL | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity%3A-abbv-fcx-ual | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 40,982 contracts has been traded thus far today, a contract volume which is representative of approximately 4.1 million underlying shares (given that every ... | Especially high volume was seen for the $140 strike call option expiring September 30, 2022, with 4,969 contracts trading so far today, representing approximately 496,900 underlying shares of ABBV. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie In... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 40,982 contracts has been traded thus far today, a contract volume which is representative of approximately 4.1 million underlying shares (given that every ... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 40,982 contracts has been traded thus far today, a contract volume which is representative of approximately 4.1 million underlying shares (given that every ... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 40,982 contracts has been traded thus far today, a contract volume which is representative of approximately 4.1 million underlying shares (given that every ... |
23,099 | 2022-09-30 00:00:00 UTC | Where Will AbbVie Be in 3 Years? | ABBV | https://www.nasdaq.com/articles/where-will-abbvie-be-in-3-years | null | null | In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The stock defied the bear market -- and even gained more than 6%.
The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neurosc... | AbbVie is working toward the approval of Rinvoq and/or Skyrizi for all of Humira's major indications -- with the addition of atopic dermatitis. Double-digit growth AbbVie's neuroscience business includes drugs such as Qulipta for migraine and Vraylar for bipolar disorder. In spite of market turmoil, this year has been ... | At the same time, AbbVie's immunology drugs Rinvoq and Skyrizi are growing. And in 2025, AbbVie expects Rinvoq's and Skyrizi's combined sales to reach $15 billion, FiercePharma reported. Double-digit growth AbbVie's neuroscience business includes drugs such as Qulipta for migraine and Vraylar for bipolar disorder. | Last year, Humira accounted for more than 36% of AbbVie's total revenue. In spite of AbbVie's gains this year, the stock still looks cheap. AbbVie's pipeline and current blockbusters could keep this company growing in three years -- and beyond. | At the same time, AbbVie's immunology drugs Rinvoq and Skyrizi are growing. AbbVie's pipeline and current blockbusters could keep this company growing in three years -- and beyond. In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.